x | QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2017 |
¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO |
Delaware | 22-0790350 | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
PART I—FINANCIAL INFORMATION | |
Item 1. | |
Item 2. | |
Item 3. | |
Item 4. | |
PART II—OTHER INFORMATION | |
Item 1. | |
Item 1A. | |
Item 2. | |
Item 6. | |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
EARNINGS | 2017 | 2016 | 2017 | 2016 | |||||||||||
Net product sales | $ | 4,862 | $ | 4,492 | $ | 14,212 | $ | 12,888 | |||||||
Alliance and other revenues | 392 | 430 | 1,115 | 1,296 | |||||||||||
Total Revenues | 5,254 | 4,922 | 15,327 | 14,184 | |||||||||||
Cost of products sold | 1,572 | 1,305 | 4,393 | 3,563 | |||||||||||
Marketing, selling and administrative | 1,147 | 1,144 | 3,388 | 3,450 | |||||||||||
Research and development | 1,543 | 1,138 | 4,490 | 3,540 | |||||||||||
Other (income)/expense | (191 | ) | (224 | ) | (1,377 | ) | (1,198 | ) | |||||||
Total Expenses | 4,071 | 3,363 | 10,894 | 9,355 | |||||||||||
Earnings Before Income Taxes | 1,183 | 1,559 | 4,433 | 4,829 | |||||||||||
Provision for Income Taxes | 327 | 344 | 1,129 | 1,220 | |||||||||||
Net Earnings | 856 | 1,215 | 3,304 | 3,609 | |||||||||||
Net Earnings/(Loss) Attributable to Noncontrolling Interest | 11 | 13 | (31 | ) | 46 | ||||||||||
Net Earnings Attributable to BMS | $ | 845 | $ | 1,202 | $ | 3,335 | $ | 3,563 | |||||||
Earnings per Common Share | |||||||||||||||
Basic | $ | 0.52 | $ | 0.72 | $ | 2.02 | $ | 2.13 | |||||||
Diluted | $ | 0.51 | $ | 0.72 | $ | 2.02 | $ | 2.12 | |||||||
Cash dividends declared per common share | $ | 0.39 | $ | 0.38 | $ | 1.17 | $ | 1.14 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
COMPREHENSIVE INCOME | 2017 | 2016 | 2017 | 2016 | |||||||||||
Net Earnings | $ | 856 | $ | 1,215 | $ | 3,304 | $ | 3,609 | |||||||
Other Comprehensive Income/(Loss), net of taxes and reclassifications to earnings: | |||||||||||||||
Derivatives qualifying as cash flow hedges | (1 | ) | 4 | (61 | ) | (126 | ) | ||||||||
Pension and postretirement benefits | 18 | 72 | 74 | (213 | ) | ||||||||||
Available-for-sale securities | 22 | (8 | ) | 41 | 46 | ||||||||||
Foreign currency translation | 7 | 1 | 28 | 26 | |||||||||||
Other Comprehensive Income/(Loss) | 46 | 69 | 82 | (267 | ) | ||||||||||
Comprehensive Income | 902 | 1,284 | 3,386 | 3,342 | |||||||||||
Comprehensive Income/(Loss) Attributable to Noncontrolling Interest | 11 | 13 | (31 | ) | 46 | ||||||||||
Comprehensive Income Attributable to BMS | $ | 891 | $ | 1,271 | $ | 3,417 | $ | 3,296 |
ASSETS | September 30, 2017 | December 31, 2016 | |||||
Current Assets: | |||||||
Cash and cash equivalents | $ | 4,644 | $ | 4,237 | |||
Marketable securities | 2,478 | 2,113 | |||||
Receivables | 5,922 | 5,543 | |||||
Inventories | 1,250 | 1,241 | |||||
Prepaid expenses and other | 754 | 570 | |||||
Total Current Assets | 15,048 | 13,704 | |||||
Property, plant and equipment | 5,014 | 4,980 | |||||
Goodwill | 6,865 | 6,875 | |||||
Other intangible assets | 1,213 | 1,385 | |||||
Deferred income taxes | 2,346 | 2,996 | |||||
Marketable securities | 2,526 | 2,719 | |||||
Other assets | 965 | 1,048 | |||||
Total Assets | $ | 33,977 | $ | 33,707 | |||
LIABILITIES | |||||||
Current Liabilities: | |||||||
Short-term debt obligations | $ | 1,461 | $ | 992 | |||
Accounts payable | 1,699 | 1,664 | |||||
Accrued liabilities | 5,418 | 5,271 | |||||
Deferred income | 647 | 762 | |||||
Income taxes payable | 213 | 152 | |||||
Total Current Liabilities | 9,438 | 8,841 | |||||
Deferred income | 492 | 547 | |||||
Income taxes payable | 996 | 973 | |||||
Pension and other liabilities | 1,155 | 1,283 | |||||
Long-term debt | 6,982 | 5,716 | |||||
Total Liabilities | 19,063 | 17,360 | |||||
Commitments and contingencies (Note 17) | |||||||
EQUITY | |||||||
Bristol-Myers Squibb Company Shareholders’ Equity: | |||||||
Preferred stock | — | — | |||||
Common stock | 221 | 221 | |||||
Capital in excess of par value of stock | 1,845 | 1,725 | |||||
Accumulated other comprehensive loss | (2,421 | ) | (2,503 | ) | |||
Retained earnings | 34,141 | 33,513 | |||||
Less cost of treasury stock | (19,003 | ) | (16,779 | ) | |||
Total Bristol-Myers Squibb Company Shareholders’ Equity | 14,783 | 16,177 | |||||
Noncontrolling interest | 131 | 170 | |||||
Total Equity | 14,914 | 16,347 | |||||
Total Liabilities and Equity | $ | 33,977 | $ | 33,707 |
Nine Months Ended September 30, | |||||||
2017 | 2016 | ||||||
Cash Flows From Operating Activities: | |||||||
Net earnings | $ | 3,304 | $ | 3,609 | |||
Adjustments to reconcile net earnings to net cash provided by operating activities: | |||||||
Depreciation and amortization, net | 592 | 260 | |||||
Deferred income taxes | 283 | (500 | ) | ||||
Stock-based compensation | 149 | 149 | |||||
Impairment charges | 223 | 75 | |||||
Pension settlements and amortization | 148 | 122 | |||||
Divestiture gains and royalties | (546 | ) | (1,082 | ) | |||
Asset acquisition charges | 510 | 274 | |||||
Other adjustments | 108 | (56 | ) | ||||
Changes in operating assets and liabilities: | |||||||
Receivables | (539 | ) | (896 | ) | |||
Inventories | 7 | (107 | ) | ||||
Accounts payable | 63 | (142 | ) | ||||
Deferred income | (91 | ) | 445 | ||||
Income taxes payable | 400 | (183 | ) | ||||
Other | (453 | ) | (353 | ) | |||
Net Cash Provided by Operating Activities | 4,158 | 1,615 | |||||
Cash Flows From Investing Activities: | |||||||
Sale and maturities of marketable securities | 4,296 | 3,674 | |||||
Purchase of marketable securities | (4,434 | ) | (2,248 | ) | |||
Capital expenditures | (801 | ) | (844 | ) | |||
Divestiture and other proceeds | 526 | 1,193 | |||||
Acquisition and other payments | (672 | ) | (311 | ) | |||
Net Cash Provided by/(Used in) Investing Activities | (1,085 | ) | 1,464 | ||||
Cash Flows From Financing Activities: | |||||||
Short-term debt obligations, net | 1,198 | 102 | |||||
Issuance of long-term debt | 1,488 | — | |||||
Repayment of long-term debt | (1,224 | ) | — | ||||
Repurchase of common stock | (2,220 | ) | (231 | ) | |||
Dividends | (1,938 | ) | (1,912 | ) | |||
Other | (29 | ) | (7 | ) | |||
Net Cash Used in Financing Activities | (2,725 | ) | (2,048 | ) | |||
Effect of Exchange Rates on Cash and Cash Equivalents | 59 | 16 | |||||
Increase in Cash and Cash Equivalents | 407 | 1,047 | |||||
Cash and Cash Equivalents at Beginning of Period | 4,237 | 2,385 | |||||
Cash and Cash Equivalents at End of Period | $ | 4,644 | $ | 3,432 |
Accounting Standard Update | Effective Date |
Recognition and Measurement of Financial Assets and Liabilities | January 1, 2018 |
Definition of a Business | January 1, 2018 |
Leases | January 1, 2019 |
Financial Instruments - Measurement of Credit Losses | January 1, 2020 |
Goodwill Impairment Testing | January 1, 2020 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
Dollars in Millions | 2017 | 2016 | 2017 | 2016 | |||||||||||
Prioritized Brands | |||||||||||||||
Opdivo | $ | 1,265 | $ | 920 | $ | 3,587 | $ | 2,464 | |||||||
Eliquis | 1,232 | 884 | 3,509 | 2,395 | |||||||||||
Orencia | 632 | 572 | 1,817 | 1,640 | |||||||||||
Sprycel | 509 | 472 | 1,478 | 1,330 | |||||||||||
Yervoy | 323 | 285 | 975 | 789 | |||||||||||
Empliciti | 60 | 41 | 168 | 103 | |||||||||||
Established Brands | |||||||||||||||
Hepatitis C Franchise | 73 | 379 | 347 | 1,352 | |||||||||||
Baraclude | 264 | 306 | 819 | 896 | |||||||||||
Sustiva Franchise | 183 | 275 | 555 | 819 | |||||||||||
Reyataz Franchise | 174 | 238 | 555 | 706 | |||||||||||
Other Brands | 539 | 550 | 1,517 | 1,690 | |||||||||||
Total Revenues | $ | 5,254 | $ | 4,922 | $ | 15,327 | $ | 14,184 | |||||||
Net product sales | $ | 4,862 | $ | 4,492 | $ | 14,212 | $ | 12,888 | |||||||
Alliance revenues | 334 | 402 | 957 | 1,229 | |||||||||||
Other revenues | 58 | 28 | 158 | 67 | |||||||||||
Total Revenues | $ | 5,254 | $ | 4,922 | $ | 15,327 | $ | 14,184 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
Dollars in Millions | 2017 | 2016 | 2017 | 2016 | |||||||||||
Revenues from alliances: | |||||||||||||||
Net product sales | $ | 1,764 | $ | 1,465 | $ | 5,045 | $ | 4,031 | |||||||
Alliance revenues | 334 | 402 | 957 | 1,229 | |||||||||||
Total Revenues | $ | 2,098 | $ | 1,867 | $ | 6,002 | $ | 5,260 | |||||||
Payments to/(from) alliance partners: | |||||||||||||||
Cost of products sold | $ | 678 | $ | 572 | $ | 1,969 | $ | 1,543 | |||||||
Marketing, selling and administrative | (16 | ) | (3 | ) | (39 | ) | (10 | ) | |||||||
Research and development | (12 | ) | (7 | ) | (6 | ) | 23 | ||||||||
Other (income)/expense | (151 | ) | (160 | ) | (545 | ) | (864 | ) | |||||||
Noncontrolling interest, pretax | 4 | 3 | 9 | 13 |
Selected Alliance Balance Sheet information: | |||||||
Dollars in Millions | September 30, 2017 | December 31, 2016 | |||||
Receivables - from alliance partners | $ | 878 | $ | 903 | |||
Accounts payable - to alliance partners | 634 | 555 | |||||
Deferred income from alliances(a) | 1,060 | 1,194 |
(a) | Includes unamortized upfront, milestone and other licensing proceeds, revenue deferrals attributed to Atripla* and undelivered elements of diabetes business divestiture proceeds. Amortization of deferred income (primarily related to alliances) was $59 million and $193 million for the nine months ended September 30, 2017 and 2016, respectively. |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
Dollars in Millions | 2017 | 2016 | 2017 | 2016 | |||||||||||
Interest expense | $ | 48 | $ | 42 | $ | 145 | $ | 127 | |||||||
Investment income | (37 | ) | (32 | ) | (104 | ) | (81 | ) | |||||||
Provision for restructuring | 28 | 19 | 207 | 41 | |||||||||||
Litigation and other settlements(a) | — | (1 | ) | (489 | ) | 48 | |||||||||
Equity in net income of affiliates | (21 | ) | (19 | ) | (59 | ) | (65 | ) | |||||||
Divestiture (gains)/losses | 1 | (21 | ) | (126 | ) | (574 | ) | ||||||||
Royalties and licensing income(b) | (209 | ) | (158 | ) | (1,093 | ) | (579 | ) | |||||||
Transition and other service fees | (12 | ) | (57 | ) | (32 | ) | (184 | ) | |||||||
Pension charges | 22 | 19 | 91 | 66 | |||||||||||
Intangible asset impairments | — | — | — | 15 | |||||||||||
Equity investment impairment | — | — | — | 45 | |||||||||||
Loss on debt redemption | — | — | 109 | — | |||||||||||
Other | (11 | ) | (16 | ) | (26 | ) | (57 | ) | |||||||
Other (income)/expense | $ | (191 | ) | $ | (224 | ) | $ | (1,377 | ) | $ | (1,198 | ) |
(a) | Includes BMS's share of a patent-infringement litigation settlement of $481 million related to Merck's PD-1 antibody Keytruda* in the nine months ended September 30, 2017. |
(b) | Includes upfront licensing fees of $470 million from Biogen and Roche in the nine months ended September 30, 2017. |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
Dollars in Millions | 2017 | 2016 | 2017 | 2016 | |||||||||||
Employee termination costs | $ | 18 | $ | 17 | $ | 190 | $ | 32 | |||||||
Other termination costs | 10 | 2 | 17 | 9 | |||||||||||
Provision for restructuring | 28 | 19 | 207 | 41 | |||||||||||
Accelerated depreciation | 64 | 15 | 216 | 42 | |||||||||||
Asset impairments | 1 | — | 144 | — | |||||||||||
Other shutdown costs | — | 6 | 3 | 13 | |||||||||||
Total charges | $ | 93 | $ | 40 | $ | 570 | $ | 96 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
Dollars in Millions | 2017 | 2016 | 2017 | 2016 | |||||||||||
Cost of products sold | $ | 1 | $ | 7 | $ | 131 | $ | 15 | |||||||
Research and development | 64 | 14 | 232 | 40 | |||||||||||
Other (income)/expense | 28 | 19 | 207 | 41 | |||||||||||
Total charges | $ | 93 | $ | 40 | $ | 570 | $ | 96 |
Nine Months Ended September 30, | |||||||
Dollars in Millions | 2017 | 2016 | |||||
Liability at January 1 | $ | 114 | $ | 125 | |||
Charges | 233 | 48 | |||||
Change in estimates | (26 | ) | (7 | ) | |||
Provision for restructuring | 207 | 41 | |||||
Foreign currency translation | 17 | 2 | |||||
Spending | (179 | ) | (88 | ) | |||
Liability at September 30 | $ | 159 | $ | 80 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
Dollars in Millions | 2017 | 2016 | 2017 | 2016 | |||||||||||
Earnings Before Income Taxes | $ | 1,183 | $ | 1,559 | $ | 4,433 | $ | 4,829 | |||||||
Provision for Income Taxes | 327 | 344 | 1,129 | 1,220 | |||||||||||
Effective Tax Rate | 27.6 | % | 22.1 | % | 25.5 | % | 25.3 | % |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
Amounts in Millions, Except Per Share Data | 2017 | 2016 | 2017 | 2016 | |||||||||||
Net Earnings Attributable to BMS used for Basic and Diluted EPS Calculation | $ | 845 | $ | 1,202 | $ | 3,335 | $ | 3,563 | |||||||
Weighted-average common shares outstanding – basic | 1,639 | 1,671 | 1,648 | 1,670 | |||||||||||
Incremental shares attributable to share-based compensation plans | 6 | 8 | 7 | 9 | |||||||||||
Weighted-average common shares outstanding – diluted | 1,645 | 1,679 | 1,655 | 1,679 | |||||||||||
Earnings per Common Share: | |||||||||||||||
Basic | $ | 0.52 | $ | 0.72 | $ | 2.02 | $ | 2.13 | |||||||
Diluted | $ | 0.51 | $ | 0.72 | $ | 2.02 | $ | 2.12 |
September 30, 2017 | December 31, 2016 | ||||||||||||||
Dollars in Millions | Level 1 | Level 2 | Level 1 | Level 2 | |||||||||||
Cash and cash equivalents - Money market and other securities | $ | — | $ | 3,915 | $ | — | $ | 3,532 | |||||||
Marketable securities: | |||||||||||||||
Certificates of deposit | — | 176 | — | 27 | |||||||||||
Commercial paper | — | 977 | — | 750 | |||||||||||
Corporate debt securities | — | 3,725 | — | 3,947 | |||||||||||
Equity funds | — | 119 | — | 101 | |||||||||||
Fixed income funds | — | 7 | — | 7 | |||||||||||
Derivative assets | — | 31 | — | 75 | |||||||||||
Equity investments | 90 | — | 24 | — | |||||||||||
Derivative liabilities | — | (63 | ) | — | (30 | ) |
September 30, 2017 | December 31, 2016 | ||||||||||||||||||||||||||||||
Dollars in Millions | Amortized Cost | Gross Unrealized | Amortized Cost | Gross Unrealized | |||||||||||||||||||||||||||
Gains | Losses | Fair Value | Gains | Losses | Fair Value | ||||||||||||||||||||||||||
Certificates of deposit | $ | 176 | $ | — | $ | — | $ | 176 | $ | 27 | $ | — | $ | — | $ | 27 | |||||||||||||||
Commercial paper | 977 | — | — | 977 | 750 | — | — | 750 | |||||||||||||||||||||||
Corporate debt securities | 3,713 | 15 | (3 | ) | 3,725 | 3,945 | 10 | (8 | ) | 3,947 | |||||||||||||||||||||
Equity investments | 57 | 34 | (1 | ) | 90 | 31 | — | (7 | ) | 24 | |||||||||||||||||||||
$ | 4,923 | $ | 49 | $ | (4 | ) | $ | 4,968 | $ | 4,753 | $ | 10 | $ | (15 | ) | $ | 4,748 | ||||||||||||||
Financial assets measured using the fair value option | |||||||||||||||||||||||||||||||
Equity and fixed income funds(a) | 126 | 108 | |||||||||||||||||||||||||||||
Total | $ | 5,094 | $ | 4,856 |
Dollars in Millions | September 30, 2017 | December 31, 2016 | |||||
Current marketable securities | $ | 2,478 | $ | 2,113 | |||
Non-current marketable securities(b) | 2,526 | 2,719 | |||||
Other assets(c) | 90 | 24 | |||||
Total | $ | 5,094 | $ | 4,856 |
(a) | The fair value option for financial assets was elected for investments in equity and fixed income funds and are included in current marketable securities. |
(b) | All non-current marketable securities mature within five years as of September 30, 2017 and December 31, 2016. |
(c) | Includes equity investments. |
September 30, 2017 | December 31, 2016 | ||||||||||||||||||||||||||||||
Asset(a) | Liability(b) | Asset(a) | Liability(b) | ||||||||||||||||||||||||||||
Dollars in Millions | Notional | Fair Value | Notional | Fair Value | Notional | Fair Value | Notional | Fair Value | |||||||||||||||||||||||
Derivatives designated as hedging instruments: | |||||||||||||||||||||||||||||||
Interest rate swap contracts | $ | — | $ | — | $ | 755 | $ | (3 | ) | $ | 750 | $ | 1 | $ | 755 | $ | (3 | ) | |||||||||||||
Forward starting interest rate swap contracts | — | — | — | — | 500 | 8 | 250 | (11 | ) | ||||||||||||||||||||||
Foreign currency forward contracts | 1,351 | 25 | 548 | (28 | ) | 967 | 66 | 198 | (9 | ) | |||||||||||||||||||||
Derivatives not designated as hedging instruments: | |||||||||||||||||||||||||||||||
Foreign currency forward contracts | 322 | 6 | 1,183 | (32 | ) | 106 | — | 360 | (7 | ) |
(a) | Included in prepaid expenses and other and other assets. |
(b) | Included in accrued liabilities and pension and other liabilities. |
Dollars in Millions | September 30, 2017 | December 31, 2016 | |||||
Commercial paper | $ | 799 | $ | — | |||
Bank drafts and short-term borrowings | 662 | 243 | |||||
Current portion of long-term debt | — | 749 | |||||
Total | $ | 1,461 | $ | 992 |
Dollars in Millions | September 30, 2017 | December 31, 2016 | |||||
Principal Value | $ | 6,834 | $ | 6,261 | |||
Adjustments to Principal Value: | |||||||
Fair value of interest rate swap contracts | (3 | ) | (2 | ) | |||
Unamortized basis adjustment from swap terminations | 234 | 287 | |||||
Unamortized bond discounts and issuance costs | (83 | ) | (81 | ) | |||
Total | $ | 6,982 | $ | 6,465 | |||
Current portion of long-term debt | $ | — | $ | 749 | |||
Long-term debt | 6,982 | 5,716 |
Dollars in Millions | 2017 | ||
Principal Value: | |||
1.600% Notes due 2019 | $ | 750 | |
3.250% Notes due 2027 | 750 | ||
Total | $ | 1,500 | |
Proceeds net of discount and deferred loan issuance costs | $ | 1,488 |
Dollars in Millions | 2017 | ||
Principal amount | $ | 337 | |
Carrying value | 366 | ||
Debt redemption price | 474 | ||
Loss on debt redemption(a) | 109 |
(a) | Including acceleration of debt issuance costs, gain on previously terminated interest rate swap contracts and other related fees. |
Dollars in Millions | September 30, 2017 | December 31, 2016 | |||||
Trade receivables | $ | 4,564 | $ | 3,948 | |||
Less charge-backs and cash discounts | (184 | ) | (126 | ) | |||
Less bad debt allowances | (48 | ) | (48 | ) | |||
Net trade receivables | 4,332 | 3,774 | |||||
Alliance receivables | 878 | 903 | |||||
Prepaid and refundable income taxes | 334 | 627 | |||||
Other | 378 | 239 | |||||
Receivables | $ | 5,922 | $ | 5,543 |
Dollars in Millions | September 30, 2017 | December 31, 2016 | |||||
Finished goods | $ | 380 | $ | 310 | |||
Work in process | 956 | 988 | |||||
Raw and packaging materials | 224 | 264 | |||||
Total inventories | $ | 1,560 | $ | 1,562 | |||
Inventories | $ | 1,250 | $ | 1,241 | |||
Other assets | 310 | 321 |
Dollars in Millions | September 30, 2017 | December 31, 2016 | |||||
Land | $ | 105 | $ | 107 | |||
Buildings | 5,188 | 4,930 | |||||
Machinery, equipment and fixtures | 3,034 | 3,287 | |||||
Construction in progress | 938 | 849 | |||||
Gross property, plant and equipment | 9,265 | 9,173 | |||||
Less accumulated depreciation | (4,251 | ) | (4,193 | ) | |||
Property, plant and equipment | $ | 5,014 | $ | 4,980 |
Dollars in Millions | September 30, 2017 | December 31, 2016 | |||||
Licenses | $ | 564 | $ | 564 | |||
Developed technology rights | 2,357 | 2,357 | |||||
Capitalized software | 1,339 | 1,441 | |||||
IPRD | 32 | 107 | |||||
Gross other intangible assets | 4,292 | 4,469 | |||||
Less accumulated amortization | (3,079 | ) | (3,084 | ) | |||
Other intangible assets | $ | 1,213 | $ | 1,385 |
Dollars in Millions | September 30, 2017 | December 31, 2016 | ||||||
Rebates and returns | $ | 1,901 | $ | 1,680 | ||||
Employee compensation and benefits | 702 | 818 | ||||||
Research and development | 689 | 718 | ||||||
Dividends | 639 | 660 | ||||||
Branded Prescription Drug Fee | 251 | 234 | ||||||
Royalties | 249 | 246 | ||||||
Restructuring | 121 | 90 | ||||||
Pension and postretirement benefits | 41 | 44 | ||||||
Litigation and other settlements | 35 | 43 | ||||||
Other | 790 | 738 | ||||||
Accrued liabilities | $ | 5,418 | $ | 5,271 |
Common Stock | Capital in Excess of Par Value of Stock | Accumulated Other Comprehensive Loss | Retained Earnings | Treasury Stock | Noncontrolling Interest | ||||||||||||||||||||||||
Dollars and Shares in Millions | Shares | Par Value | Shares | Cost | |||||||||||||||||||||||||
Balance at January 1, 2016 | 2,208 | $ | 221 | $ | 1,459 | $ | (2,468 | ) | $ | 31,613 | 539 | $ | (16,559 | ) | $ | 158 | |||||||||||||
Net earnings | — | — | — | — | 3,563 | — | — | 46 | |||||||||||||||||||||
Other comprehensive loss | — | — | — | (267 | ) | — | — | — | — | ||||||||||||||||||||
Cash dividends declared | — | — | — | — | (1,904 | ) | — | — | — | ||||||||||||||||||||
Stock repurchase program | — | — | — | — | — | 4 | (231 | ) | — | ||||||||||||||||||||
Stock compensation | — | — | 191 | — | — | (6 | ) | (5 | ) | — | |||||||||||||||||||
Distributions | — | — | — | — | — | — | — | (36 | ) | ||||||||||||||||||||
Balance at September 30, 2016 | 2,208 | $ | 221 | $ | 1,650 | $ | (2,735 | ) | $ | 33,272 | 537 | $ | (16,795 | ) | $ | 168 | |||||||||||||
Balance at December 31, 2016 | 2,208 | $ | 221 | $ | 1,725 | $ | (2,503 | ) | $ | 33,513 | 536 | $ | (16,779 | ) | $ | 170 | |||||||||||||
Accounting change - cumulative effect(a) | — | — | — | — | (787 | ) | — | — | — | ||||||||||||||||||||
Adjusted balance at January 1, 2017 | 2,208 | $ | 221 | $ | 1,725 | $ | (2,503 | ) | $ | 32,726 | 536 | $ | (16,779 | ) | $ | 170 | |||||||||||||
Net earnings | — | — | — | — | 3,335 | — | — | 28 | |||||||||||||||||||||
Other comprehensive income | — | — | — | 82 | — | — | — | — | |||||||||||||||||||||
Cash dividends declared | — | — | — | — | (1,920 | ) | — | — | — | ||||||||||||||||||||
Stock repurchase program | — | — | — | — | — | 40 | (2,226 | ) | — | ||||||||||||||||||||
Stock compensation | — | — | 120 | — | — | (5 | ) | 2 | — | ||||||||||||||||||||
Variable interest entity | — | — | — | — | — | — | — | (59 | ) | ||||||||||||||||||||
Distributions | — | — | — | — | — | — | — | (8 | ) | ||||||||||||||||||||
Balance at September 30, 2017 | 2,208 | $ | 221 | $ | 1,845 | $ | (2,421 | ) | $ | 34,141 | 571 | $ | (19,003 | ) | $ | 131 |
(a) | Refer to "—Note 1. Basis of Presentation and Recently Issued Accounting Standards" for additional information. |
2017 | 2016 | ||||||||||||||||||||||
Pretax | Tax | After tax | Pretax | Tax | After tax | ||||||||||||||||||
Three Months Ended September 30, | |||||||||||||||||||||||
Derivatives qualifying as cash flow hedges: | |||||||||||||||||||||||
Unrealized losses | $ | (28 | ) | $ | 12 | $ | (16 | ) | $ | (14 | ) | $ | 4 | $ | (10 | ) | |||||||
Reclassified to net earnings(a) | 21 | (6 | ) | 15 | 21 | (7 | ) | 14 | |||||||||||||||
Derivatives qualifying as cash flow hedges | (7 | ) | 6 | (1 | ) | 7 | (3 | ) | 4 | ||||||||||||||
Pension and postretirement benefits: | |||||||||||||||||||||||
Actuarial gains/(losses) | (5 | ) | 2 | (3 | ) | 72 | (26 | ) | 46 | ||||||||||||||
Amortization(b) | 19 | (11 | ) | 8 | 20 | (7 | ) | 13 | |||||||||||||||
Curtailments and settlements(c) | 21 | (8 | ) | 13 | 19 | (6 | ) | 13 | |||||||||||||||
Pension and postretirement benefits | 35 | (17 | ) | 18 | 111 | (39 | ) | 72 | |||||||||||||||
Available-for-sale securities: | |||||||||||||||||||||||
Unrealized gains/(losses) | 28 | (5 | ) | 23 | (8 | ) | 4 | (4 | ) | ||||||||||||||
Realized gains(c) | (1 | ) | — | (1 | ) | (4 | ) | — | (4 | ) | |||||||||||||
Available-for-sale securities | 27 | (5 | ) | 22 | (12 | ) | 4 | (8 | ) | ||||||||||||||
Foreign currency translation | (10 | ) | 17 | 7 | (2 | ) | 3 | 1 | |||||||||||||||
$ | 45 | $ | 1 | $ | 46 | $ | 104 | $ | (35 | ) | $ | 69 | |||||||||||
Nine Months Ended September 30, | |||||||||||||||||||||||
Derivatives qualifying as cash flow hedges: | |||||||||||||||||||||||
Unrealized losses | $ | (81 | ) | $ | 31 | $ | (50 | ) | $ | (199 | ) | $ | 66 | $ | (133 | ) | |||||||
Reclassified to net earnings(a) | (11 | ) | — | (11 | ) | 12 | (5 | ) | 7 | ||||||||||||||
Derivatives qualifying as cash flow hedges | (92 | ) | 31 | (61 | ) | (187 | ) | 61 | (126 | ) | |||||||||||||
Pension and postretirement benefits: | |||||||||||||||||||||||
Actuarial losses | (40 | ) | 17 | (23 | ) | (453 | ) | 160 | (293 | ) | |||||||||||||
Amortization(b) | 57 | (22 | ) | 35 | 56 | (19 | ) | 37 | |||||||||||||||
Curtailments and settlements(c) | 96 | (34 | ) | 62 | 66 | (23 | ) | 43 | |||||||||||||||
Pension and postretirement benefits | 113 | (39 | ) | 74 | (331 | ) | 118 | (213 | ) | ||||||||||||||
Available-for-sale securities: | |||||||||||||||||||||||
Unrealized gains | 49 | (7 | ) | 42 | 29 | (13 | ) | 16 | |||||||||||||||
Realized (gains)/losses(c) | (1 | ) | — | (1 | ) | 30 | — | 30 | |||||||||||||||
Available-for-sale securities | 48 | (7 | ) | 41 | 59 | (13 | ) | 46 | |||||||||||||||
Foreign currency translation | (8 | ) | 36 | 28 | 20 | 6 | 26 | ||||||||||||||||
$ | 61 | $ | 21 | $ | 82 | $ | (439 | ) | $ | 172 | $ | (267 | ) |
(a) | Included in cost of products sold |
(b) | Included in cost of products sold, research and development and marketing, selling and administrative expenses |
(c) | Included in other (income)/expense |
Dollars in Millions | September 30, 2017 | December 31, 2016 | |||||
Derivatives qualifying as cash flow hedges | $ | (23 | ) | $ | 38 | ||
Pension and other postretirement benefits | (2,023 | ) | (2,097 | ) | |||
Available-for-sale securities | 34 | (7 | ) | ||||
Foreign currency translation | (409 | ) | (437 | ) | |||
Accumulated other comprehensive loss | $ | (2,421 | ) | $ | (2,503 | ) |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
Dollars in Millions | 2017 | 2016 | 2017 | 2016 | |||||||||||
Service cost – benefits earned during the year | $ | 7 | $ | 6 | $ | 19 | $ | 19 | |||||||
Interest cost on projected benefit obligation | 48 | 45 | 142 | 145 | |||||||||||
Expected return on plan assets | (104 | ) | (104 | ) | (308 | ) | (314 | ) | |||||||
Amortization of prior service credits | (1 | ) | (1 | ) | (3 | ) | (3 | ) | |||||||
Amortization of net actuarial loss | 20 | 22 | 61 | 62 | |||||||||||
Curtailments and settlements | 22 | 19 | 91 | 66 | |||||||||||
Special termination benefits | — | — | — | 1 | |||||||||||
Net periodic benefit cost/(credit) | $ | (8 | ) | $ | (13 | ) | $ | 2 | $ | (24 | ) |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
Dollars in Millions, except per share data | 2017 | 2016 | 2017 | 2016 | |||||||||||
Total Revenues | $ | 5,254 | $ | 4,922 | $ | 15,327 | $ | 14,184 | |||||||
Diluted Earnings Per Share | |||||||||||||||
GAAP | 0.51 | 0.72 | 2.02 | 2.12 | |||||||||||
Non-GAAP | 0.75 | 0.77 | 2.32 | 2.20 |
Product | Date | Approval |
Opdivo | September 2017 | FDA approval for the treatment of patients with HCC, a type of liver cancer, who have been previously treated with sorafenib. |
September 2017 | Approval in Japan for the treatment of unresectable advanced or recurrent gastric cancer which has progressed after chemotherapy, received by our alliance partner, Ono. | |
August 2017 | FDA approval for the treatment of adult and pediatric patients with MSI-H or dMMR mCRC that has progressed following treatment with a fluoropyrimidine, oxaliplatin and irinotecan. | |
June 2017 | EC approval for the treatment of patients with previously treated locally advanced unresectable or metastatic urothelial carcinoma, a type of bladder cancer, in adults after failure of platinum-containing therapy. | |
April 2017 | EC approval for the treatment of SCCHN in adults progressing on or after platinum-based therapy. | |
March 2017 | Approval in Japan for the treatment of recurrent or metastatic HNC, received by our alliance partner, Ono. | |
February 2017 | FDA approval for the treatment of patients with previously treated locally advanced or metastatic urothelial carcinoma, a type of bladder cancer. | |
Orencia | July 2017 | EC approval for the treatment of active PsA in adults for whom the response to previous disease-modifying antirheumatic drug therapy, including methotrexate, has been inadequate, and additional systemic therapy for psoriatic skin lesions is not required. |
July 2017 | FDA approval for the treatment of active PsA in adults. | |
March 2017 | FDA approval of a new subcutaneous administration option for use in patients two years of age and older with moderately to severely active polyarticular JIA. | |
Yervoy | July 2017 | FDA approval of an expanded indication for the treatment of unresectable or metastatic melanoma in pediatric patients. |
Hepatitis C Franchise | April 2017 | China FDA approval of the Daklinza and Sunvepra regimen for treatment-naive or experienced patients infected with genotype 1b chronic HCV. In addition, Daklinza was approved in China for combination use with other agents, including sofosbuvir, for adult patients with HCV genotypes 1-6 infection. |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||||||
Total Revenues | 2017 vs. 2016 | Total Revenues | 2017 vs. 2016 | ||||||||||||||||||||||||
Dollars in Millions | 2017 | 2016 | Total Change | Foreign Exchange(b) | 2017 | 2016 | Total Change | Foreign Exchange(b) | |||||||||||||||||||
United States | $ | 2,864 | $ | 2,790 | 3 | % | — | $ | 8,467 | $ | 8,015 | 6 | % | — | |||||||||||||
Europe | 1,262 | 946 | 33 | % | 5 | % | 3,596 | 2,855 | 26 | % | (1 | )% | |||||||||||||||
Rest of the World | 970 | 1,069 | (9 | )% | (2 | )% | 2,858 | 2,922 | (2 | )% | (1 | )% | |||||||||||||||
Other(a) | 158 | 117 | 35 | % | N/A | 406 | 392 | 4 | % | N/A | |||||||||||||||||
Total | $ | 5,254 | $ | 4,922 | 7 | % | 1 | % | $ | 15,327 | $ | 14,184 | 8 | % | (1 | )% |
(a) | Other revenues include royalties and alliance-related revenues for products not sold by our regional commercial organizations. |
(b) | Foreign exchange impacts were derived by applying the prior period average currency rates to the current period sales. |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||
Dollars in Millions | 2017 | 2016 | % Change | 2017 | 2016 | % Change | |||||||||||||||
Gross product sales | $ | 6,555 | $ | 5,698 | 15 | % | $ | 18,723 | $ | 16,252 | 15 | % | |||||||||
GTN adjustments: | |||||||||||||||||||||
Charge-backs and cash discounts | (583 | ) | (427 | ) | 37 | % | (1,521 | ) | (1,174 | ) | 30 | % | |||||||||
Medicaid and Medicare rebates | (573 | ) | (397 | ) | 44 | % | (1,474 | ) | (1,018 | ) | 45 | % | |||||||||
Other rebates, returns, discounts and adjustments | (537 | ) | (382 | ) | 41 | % | (1,516 | ) | (1,172 | ) | 29 | % | |||||||||
Total GTN adjustments | (1,693 | ) | (1,206 | ) | 40 | % | (4,511 | ) | (3,364 | ) | 34 | % | |||||||||
Net product sales | $ | 4,862 | $ | 4,492 | 8 | % | $ | 14,212 | $ | 12,888 | 10 | % | |||||||||
GTN adjustments percentage | 26 | % | 21 | % | 5 | % | 24 | % | 21 | % | 3 | % | |||||||||
U.S. | 32 | % | 26 | % | 6 | % | 30 | % | 26 | % | 4 | % | |||||||||
Non-U.S. | 15 | % | 14 | % | 1 | % | 14 | % | 12 | % | 2 | % |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||
Dollars in Millions | 2017 | 2016 | % Change | 2017 | 2016 | % Change | |||||||||||||||
Prioritized Brands | |||||||||||||||||||||
Opdivo | $ | 1,265 | $ | 920 | 38 | % | $ | 3,587 | $ | 2,464 | 46 | % | |||||||||
U.S. | 778 | 712 | 9 | % | 2,307 | 1,949 | 18 | % | |||||||||||||
Non-U.S. | 487 | 208 | ** | 1,280 | 515 | ** | |||||||||||||||
Eliquis | 1,232 | 884 | 39 | % | 3,509 | 2,395 | 47 | % | |||||||||||||
U.S. | 717 | 512 | 40 | % | 2,119 | 1,424 | 49 | % | |||||||||||||
Non-U.S. | 515 | 372 | 38 | % | 1,390 | 971 | 43 | % | |||||||||||||
Orencia | 632 | 572 | 10 | % | 1,817 | 1,640 | 11 | % | |||||||||||||
U.S. | 432 | 387 | 12 | % | 1,243 | 1,109 | 12 | % | |||||||||||||
Non-U.S. | 200 | 185 | 8 | % | 574 | 531 | 8 | % | |||||||||||||
Sprycel | 509 | 472 | 8 | % | 1,478 | 1,330 | 11 | % | |||||||||||||
U.S. | 278 | 259 | 7 | % | 806 | 702 | 15 | % | |||||||||||||
Non-U.S. | 231 | 213 | 8 | % | 672 | 628 | 7 | % | |||||||||||||
Yervoy | 323 | 285 | 13 | % | 975 | 789 | 24 | % | |||||||||||||
U.S. | 239 | 222 | 8 | % | 727 | 600 | 21 | % | |||||||||||||
Non-U.S. | 84 | 63 | 33 | % | 248 | 189 | 31 | % | |||||||||||||
Empliciti | 60 | 41 | 46 | % | 168 | 103 | 63 | % | |||||||||||||
U.S. | 39 | 36 | 8 | % | 112 | 97 | 15 | % | |||||||||||||
Non-U.S. | 21 | 5 | ** | 56 | 6 | ** | |||||||||||||||
Established Brands | |||||||||||||||||||||
Hepatitis C Franchise | 73 | 379 | (81 | )% | 347 | 1,352 | (74 | )% | |||||||||||||
U.S. | 24 | 192 | (88 | )% | 96 | 745 | (87 | )% | |||||||||||||
Non-U.S. | 49 | 187 | (74 | )% | 251 | 607 | (59 | )% | |||||||||||||
Baraclude | 264 | 306 | (14 | )% | 819 | 896 | (9 | )% | |||||||||||||
U.S. | 14 | 17 | (18 | )% | 40 | 49 | (18 | )% | |||||||||||||
Non-U.S. | 250 | 289 | (13 | )% | 779 | 847 | (8 | )% | |||||||||||||
Sustiva Franchise | 183 | 275 | (33 | )% | 555 | 819 | (32 | )% | |||||||||||||
U.S. | 157 | 234 | (33 | )% | 471 | 689 | (32 | )% | |||||||||||||
Non-U.S. | 26 | 41 | (37 | )% | 84 | 130 | (35 | )% | |||||||||||||
Reyataz Franchise | 174 | 238 | (27 | )% | 555 | 706 | (21 | )% | |||||||||||||
U.S. | 85 | 125 | (32 | )% | 260 | 367 | (29 | )% | |||||||||||||
Non-U.S. | 89 | 113 | (21 | )% | 295 | 339 | (13 | )% | |||||||||||||
Other Brands | 539 | 550 | (2 | )% | 1,517 | 1,690 | (10 | )% | |||||||||||||
U.S. | 101 | 94 | 7 | % | 286 | 284 | 1 | % | |||||||||||||
Non-U.S. | 438 | 456 | (4 | )% | 1,231 | 1,406 | (12 | )% |
• | U.S. revenues increased in both periods due to higher demand. We expect increased competition for Opdivo to continue in the future. |
• | International revenues increased in both periods due to higher demand as a result of launches of additional indications and approvals in new countries. |
• | U.S. and international revenues increased in both periods due to higher demand resulting from increased commercial acceptance of novel oral anticoagulants and market share gains. |
• | U.S. revenues increased in both periods due to higher average net selling prices and demand. |
• | International revenues increased in both periods due to higher demand. |
• | U.S. revenues increased in both periods primarily due to higher demand. |
• | International revenues increased in both periods due to higher demand. |
• | U.S. revenues increased in both periods primarily due to higher demand. |
• | International revenues increased in both periods due to higher demand. |
• | Empliciti was launched in the U.S. in December 2015, in the EU in May 2016 and in Japan in September 2016. |
• | U.S. and international revenues decreased in both periods due to lower demand resulting from increased competition. |
• | International revenues continued to decrease in both periods due to lower demand resulting from increased competition. |
• | U.S. revenues continued to decrease in both periods due to lower demand resulting from increased competition. The loss of exclusivity for Sustiva is expected in December 2017 which may result in the termination of the joint venture agreement with Gilead and further reduce revenues beyond 2017. |
• | U.S. revenues continued to decrease due to lower demand resulting from increased competition. The loss of exclusivity is expected in December 2017 and will result in a higher decline in revenues in future periods due to generic competition. |
• | International revenues continued to decrease in both periods due to lower demand. |
• | International revenues decreased in both periods due to out-licensing and divestiture of certain other brands and continued generic erosion. |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||
Dollars in Millions | 2017 | 2016 | % Change | 2017 | 2016 | % Change | |||||||||||||||
Cost of products sold | $ | 1,572 | $ | 1,305 | 20 | % | $ | 4,393 | $ | 3,563 | 23 | % | |||||||||
Marketing, selling and administrative | 1,147 | 1,144 | — | 3,388 | 3,450 | (2 | )% | ||||||||||||||
Research and development | 1,543 | 1,138 | 36 | % | 4,490 | 3,540 | 27 | % | |||||||||||||
Other (income)/expense | (191 | ) | (224 | ) | (15 | )% | (1,377 | ) | (1,198 | ) | 15 | % | |||||||||
Total Expenses | $ | 4,071 | $ | 3,363 | 21 | % | $ | 10,894 | $ | 9,355 | 16 | % |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
Dollars in Millions | 2017 | 2016 | 2017 | 2016 | |||||||||||
IFM | $ | 310 | $ | — | $ | 310 | $ | — | |||||||
CytomX | — | — | 200 | 10 | |||||||||||
Flexus | — | — | 93 | 100 | |||||||||||
Cardioxyl | — | — | 100 | — | |||||||||||
Padlock | — | — | — | 139 | |||||||||||
Cormorant | — | 35 | — | 35 | |||||||||||
Other | — | 10 | 50 | 25 | |||||||||||
License and asset acquisition charges | 310 | 45 | 753 | 309 | |||||||||||
IPRD impairments | — | — | 75 | — | |||||||||||
Accelerated depreciation and other | 64 | 14 | 232 | 40 |
• | License and asset acquisition charges include upfront payments for the IFM, CytomX, Padlock and Cormorant arrangements and milestone payments for the CytomX, Flexus and Cardioxyl arrangements. These arrangements were related to certain investigational oncology, cardiovascular and immunoscience compounds. |
• | IPRD impairment charges in the nine months ended September 30, 2017 related to the discontinued development of an investigational compound which was part of our alliance with F-Star Alpha. |
• | Accelerated depreciation and other charges resulted from the expected exit of R&D sites in the U.S. through 2020 primarily due to the reduction in the estimated useful lives of the related assets for each site. |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
Dollars in Millions | 2017 | 2016 | 2017 | 2016 | |||||||||||
Provision for restructuring | $ | 28 | $ | 19 | $ | 207 | $ | 41 | |||||||
Litigation and other settlements | — | (1 | ) | (489 | ) | 48 | |||||||||
Divestiture (gains)/losses | 1 | (21 | ) | (126 | ) | (574 | ) | ||||||||
Royalties and licensing income | (209 | ) | (158 | ) | (1,093 | ) | (579 | ) | |||||||
Transition and other service fees | (12 | ) | (57 | ) | (32 | ) | (184 | ) |
• | Restructuring charges relate to changes to the Company's operating model to drive continued success in the near- and long-term through a more focused investment in commercial opportunities for key brands and markets, a competitive and more agile R&D organization that can accelerate the pipeline, streamline operations and realign manufacturing capabilities that broaden biologics capabilities to reflect the current and future portfolio as well as streamline and simplify our small-molecule supply network. The new operating model is expected to enable the Company to deliver the strategic, financial and operational flexibility necessary to invest in the highest priorities across the Company. Aggregate restructuring charges of approximately $250 million are expected to be incurred in 2017 for all actions in addition to accelerated depreciation impacts resulting from early site exits. |
• | Litigation and other settlements include BMS's share of a patent-infringement litigation settlement related to Merck's PD-1 antibody Keytruda* in the first quarter of 2017 as BMS and Ono signed a global patent license agreement with Merck. Merck made an initial payment of $625 million to BMS and Ono, of which BMS received $481 million. Merck is also obligated to pay ongoing royalties on global sales of Keytruda* of 6.5% from January 1, 2017 through December 31, 2023, and 2.5% from January 1, 2024 through December 31, 2026. The companies also granted certain rights to each other under their respective |
• | Divestiture gains include additional contingent consideration for the diabetes business ($100 million) in the first quarter of 2017, an OTC product business in the second quarter of 2016 ($277 million) and the investigational HIV medicines business in the first quarter of 2016 ($272 million). |
• | Royalties and licensing income include upfront licensing fees from Biogen ($300 million) and Roche ($170 million) in the second quarter of 2017 in connection with the out-licensing of certain investigational genetically defined disease compounds. |
• | Transition and other service fees in 2016 included fees resulting from the divestiture of the diabetes business in 2014 and the investigational HIV medicines business in 2016. |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
Dollars in Millions | 2017 | 2016 | 2017 | 2016 | |||||||||||
Earnings Before Income Taxes | $ | 1,183 | $ | 1,559 | $ | 4,433 | $ | 4,829 | |||||||
Provision for Income Taxes | 327 | 344 | 1,129 | 1,220 | |||||||||||
Effective Tax Rate | 27.6 | % | 22.1 | % | 25.5 | % | 25.3 | % |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
Dollars in Millions | 2017 | 2016 | 2017 | 2016 | |||||||||||
Impairment charges | $ | 1 | $ | — | $ | 128 | $ | — | |||||||
Accelerated depreciation and other shutdown costs | — | 7 | 3 | 15 | |||||||||||
Cost of products sold | 1 | 7 | 131 | 15 | |||||||||||
License and asset acquisition charges | 310 | 45 | 753 | 309 | |||||||||||
IPRD impairments | — | — | 75 | — | |||||||||||
Accelerated depreciation and other | 64 | 14 | 232 | 40 | |||||||||||
Research and development | 374 | 59 | 1,060 | 349 | |||||||||||
Provision for restructuring | 28 | 19 | 207 | 41 | |||||||||||
Litigation and other settlements | — | (3 | ) | (481 | ) | 40 | |||||||||
Divestiture gains | — | (13 | ) | (100 | ) | (559 | ) | ||||||||
Royalties and licensing income | — | — | (497 | ) | — | ||||||||||
Pension charges | 22 | 19 | 91 | 66 | |||||||||||
Intangible asset impairments | — | — | — | 15 | |||||||||||
Loss on debt redemption | — | — | 109 | — | |||||||||||
Other (income)/expense | 50 | 22 | (671 | ) | (397 | ) | |||||||||
Increase/(decrease) to pretax income | 425 | 88 | 520 | (33 | ) | ||||||||||
Income taxes on specified items | (41 | ) | (3 | ) | 51 | 156 | |||||||||
Increase to net earnings | 384 | 85 | 571 | 123 | |||||||||||
Noncontrolling interest | — | — | (59 | ) | — | ||||||||||
Increase to net earnings used for Diluted Non-GAAP EPS calculation | $ | 384 | $ | 85 | $ | 512 | $ | 123 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
Dollars in Millions, except per share data | 2017 | 2016 | 2017 | 2016 | |||||||||||
Net Earnings Attributable to BMS used for Diluted EPS Calculation – GAAP | $ | 845 | $ | 1,202 | $ | 3,335 | $ | 3,563 | |||||||
Specified Items | 384 | 85 | 512 | 123 | |||||||||||
Net Earnings used for Diluted EPS Calculation – Non-GAAP | $ | 1,229 | $ | 1,287 | $ | 3,847 | $ | 3,686 | |||||||
Average Common Shares Outstanding – Diluted | 1,645 | 1,679 | 1,655 | 1,679 | |||||||||||
Diluted Earnings Per Share – GAAP | $ | 0.51 | $ | 0.72 | $ | 2.02 | $ | 2.12 | |||||||
Diluted EPS Attributable to Specified Items | 0.24 | 0.05 | 0.30 | 0.08 | |||||||||||
Diluted Earnings Per Share – Non-GAAP | $ | 0.75 | $ | 0.77 | $ | 2.32 | $ | 2.20 |
Dollars in Millions | September 30, 2017 | December 31, 2016 | |||||
Cash and cash equivalents | $ | 4,644 | $ | 4,237 | |||
Marketable securities – current | 2,478 | 2,113 | |||||
Marketable securities – non-current | 2,526 | 2,719 | |||||
Cash, cash equivalents and marketable securities | 9,648 | 9,069 | |||||
Short-term debt obligations | (1,461 | ) | (992 | ) | |||
Long-term debt | (6,982 | ) | (5,716 | ) | |||
Net cash position | $ | 1,205 | $ | 2,361 |
Nine Months Ended September 30, | |||||||
Dollars in Millions | 2017 | 2016 | |||||
Cash flow provided by/(used in): | |||||||
Operating activities | $ | 4,158 | $ | 1,615 | |||
Investing activities | (1,085 | ) | 1,464 | ||||
Financing activities | (2,725 | ) | (2,048 | ) |
• | Lower income tax payments of approximately $1.4 billion; |
• | Higher out-license proceeds of approximately $500 million primarily related to the Biogen and Roche transactions; and |
• | BMS's share of litigation settlement proceeds of $481 million related to Merck's PD-1 antibody Keytruda*. |
• | Higher R&D licensing payments of approximately $300 million primarily due to the CytomX transaction. |
• | Lower net sales of marketable securities with maturities greater than 90 days of $1.6 billion due to higher available cash balances; |
• | Lower business divestiture proceeds of approximately $700 million primarily due to certain OTC products and investigational HIV business divestitures in 2016; and |
• | Higher asset acquisition payments of approximately $400 million primarily due to the acquisition of IFM in 2017. |
• | Higher repurchase of common stock of $2.0 billion primarily due to the accelerated share repurchase agreements. |
• | Higher net borrowings of $1.4 billion primarily to fund the repurchase of common stock. |
Product | Indication | Date | Developments |
Opdivo | Gastric | September 2017 | Approval in Japan for the treatment of unresectable advanced or recurrent gastric cancer which has progressed after chemotherapy, received by our alliance partner, Ono. |
HCC | September 2017 | FDA approval for the treatment of patients with HCC, a type of liver cancer, who have been previously treated with sorafenib. | |
mCRC | August 2017 | FDA approval for the treatment of adult and pediatric patients with MSI-H or dMMR mCRC that has progressed following treatment with a fluoropyrimidine, oxaliplatin and irinotecan. | |
Melanoma | October 2017 | Announced FDA accepted for priority review the Company's sBLA for Opdivo to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection. The FDA action date is February 14, 2018. | |
September 2017 | Announced treatment with Opdivo resulted in significant improvement in recurrence-free survival compared to Yervoy in patients with stage IIIb/c or stage IV melanoma following complete surgical resection. | ||
July 2017 | Announced a Phase III trial evaluating Opdivo versus Yervoy in patients with stage IIIb/c or stage IV melanoma who are at high risk of recurrence following complete surgical resection met its primary endpoint of recurrence-free survival at a planned interim analysis. | ||
Multiple Myeloma | September 2017 | Announced the FDA placed a partial clinical hold on CheckMate-602, CheckMate-039 and CA204142, three clinical trials investigating Opdivo based combinations in patients with relapsed or refractory multiple myeloma. This partial clinical hold is related to risks identified in trials studying another anti-PD-1 agent, pembrolizumab, in patients with multiple myeloma. | |
NSCLC | September 2017 | Announced three-year overall survival data from CheckMate-017 and CheckMate-057, two pivotal Phase III randomized studies evaluating Opdivo vs. docetaxel in patients with previously treated metastatic NSCLC. | |
Various | July 2017 | BMS and Clovis Oncology, Inc. announced a clinical collaboration to evaluate the combination of Opdivo and Rubraca* (rucaparib) in pivotal Phase III trials in advanced ovarian cancer and triple-negative breast cancer as well as a Phase II trial in metastatic castration-resistant prostate cancer. | |
Announced FDA accepted the Company's sBLAs to update Opdivo dosing to include 480 mg infused over 30 minutes every four weeks for all currently approved monotherapy indications. The FDA action date is March 5, 2018. | |||
Opdivo+Yervoy | RCC | September 2017 | Announced CheckMate-214, a Phase III study evaluating Opdivo+Yervoy versus sunitinib in patients with previously untreated advanced or metastatic RCC, met its co-primary endpoint, demonstrating superior overall survival in intermediate- and poor-risk patients. The combination also met a secondary endpoint of improved OS in all randomized patients. Based on a planned interim analysis, an independent Data Monitoring Committee has recommended that the trial be stopped early. |
August 2017 | Announced topline results from CheckMate-214. The combination of Opdivo+Yervoy met the co-primary endpoint of objective response rate and was favored in the co-primary endpoint of progression-free survival, however, it did not reach statistical significance. | ||
July 2017 | BMS and Exelixis, Inc. announced the initiation of the Phase III CheckMate 9ER trial to evaluate Opdivo in combination with Cabometyx* (cabozantinib) or Opdivo and Yervoy in combination with Cabometyx* versus sunitinib in patients with previously untreated, advanced or metastatic RCC. | ||
SCLC | October 2017 | Announced data evaluating Opdivo and Opdivo+Yervoy in previously treated SCLC patients whose tumors were evaluable for tumor mutation burden from the Phase I/II CheckMate-032 trial. |
Product | Indication | Date | Developments |
Eliquis | NVAF | August 2017 | Announced results from a real-world data analysis of the U.S. Humana database, in which treatment with Eliquis was associated with a significantly lower risk of stroke/systemic embolism and lower rates of major bleeding compared to warfarin in patients aged 65 years and older with NVAF. |
Announced data from EMANATE, a Phase IV trial, exploring the safety and efficacy of Eliquis in patients with NVAF undergoing cardioversion. | |||
Announced results from a real-world data analysis pooled from four large U.S. insurance claims databases, in which treatment with Eliquis was associated with a lower risk of stroke/systemic embolism and lower rates of major bleeding compared to warfarin for the overall population and for each of the selected high-risk patient sub-populations. | |||
Orencia | PsA | July 2017 | EC approval for the treatment of active PsA in adults for whom the response to previous disease-modifying antirheumatic drug therapy, including methotrexate, has been inadequate, and additional systemic therapy for psoriatic skin lesions is not required. |
FDA approval for active PsA in adults, a chronic, inflammatory disease that can affect both the skin and musculoskeletal system. | |||
Sprycel | CML | July 2017 | Announced the FDA accepted for priority review a supplemental NDA to treat children with Philadelphia chromosome-positive chronic phase CML, as well as a powder for oral suspension formulation of Sprycel. The FDA action date is November 9, 2017. |
Yervoy | Melanoma | October 2017 | Announced the FDA added five-year overall survival data from the Phase III CA184-029 trial to the prescribing information for Yervoy for the adjuvant treatment of fully resected cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm. |
July 2017 | FDA approval of an expanded indication for the treatment of unresectable or metastatic melanoma in pediatric patients. | ||
Prostvac* | Prostate Cancer | September 2017 | Bavarian Nordic A/S announced an independent Data Monitoring Committee determined that the continuation of the Phase III PROSPECT study of Prostvac* in patients with metastatic castration-resistant prostate cancer is futile. |
Period | Total Number of Shares Purchased(a) | Average Price Paid per Share(a) | Total Number of Shares Purchased as Part of Publicly Announced Programs(b) | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Programs(b) | |||||||||
Dollars in Millions, Except Per Share Data | |||||||||||||
July 1 to 31, 2017 | 63,794 | $ | 56.63 | 52,851 | $ | 2,134 | |||||||
August 1 to 31, 2017 | 2,994,306 | $ | 57.68 | 2,985,959 | $ | 1,962 | |||||||
September 1 to 30, 2017 | 812,937 | $ | 62.53 | 803,249 | $ | 1,912 | |||||||
Three months ended September 30, 2017 | 3,871,037 | 3,842,059 |
(a) | Includes shares repurchased as part of publicly announced programs and shares of common stock surrendered to the Company to satisfy tax withholding obligations in connection with the vesting of awards under our long-term incentive program. |
(b) | In May 2010, the Board of Directors authorized the repurchase of up to $3.0 billion of common stock and in June 2012 increased its authorization for the repurchase of common stock by an additional $3.0 billion. In October 2016, the Board of Directors approved a new share repurchase program authorizing the repurchase of an additional $3.0 billion of common stock. The stock repurchase program does not have an expiration date. Refer to “Item 1. Financial Statements—Note 15. Equity" for information on the accelerated share repurchase agreements. |
Exhibit No. | Description | |
101. | The following financial statements from the Bristol-Myers Squibb Company Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, formatted in Extensible Business Reporting Language (XBRL): (i) consolidated statements of earnings, (ii) consolidated statements of comprehensive income, (iii) consolidated balance sheets, (iv) consolidated statements of cash flows, and (v) the notes to the consolidated financial statements. |
2016 Form 10-K | Annual Report on Form 10-K for the fiscal year ended December 31, 2016 |
AstraZeneca | AstraZeneca PLC |
Biogen | Biogen Inc. |
Cardioxyl | Cardioxyl Pharmaceuticals, Inc. |
CML | chronic myeloid leukemia |
CytomX | CytomX Therapeutics, Inc. |
dMMR | DNA mismatch repair deficient |
EPO | European Patent Office |
EPS | earnings per share |
EU | European Union |
FASB | Financial Accounting Standards Board |
FDA | U.S. Food and Drug Administration |
Flexus | Flexus Biosciences, Inc. |
F-Star Alpha | F-Star Alpha Ltd. |
GAAP | U.S. generally accepted accounting principles |
Gilead | Gilead Sciences, Inc. |
GTN | Gross-to-Net |
Halozyme | Halozyme Therapeutics, Inc. |
HCC | Hepatocellular carcinoma |
HIV | human immunodeficiency virus |
HNC | head and neck cancer |
IFM | IFM Therapeutics, Inc. |
iPierian | iPierian, Inc. |
IO | immuno-oncology |
IPRD | In-process research and development |
JIA | Juvenile Idiopathic Arthritis |
mCRC | metastatic colorectal cancer |
Merck | Merck & Co., Inc. |
MSI-H | microsatellite instability-high |
NDA | New Drug Application |
NKT | natural killer T cells |
NSCLC | non-small cell lung cancer |
NVAF | non-valvular atrial fibrillation |
Ono | Ono Pharmaceutical Co., Ltd. |
OTC | Over-the-counter |
Padlock | Padlock Therapeutics, Inc. |
PD-1 | programmed death receptor-1 |
PsA | active psoriatic arthritis |
Quarterly Report on Form 10-Q | Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2017 |
RA | rheumatoid arthritis |
RCC | renal cell carcinoma |
R&D | Research and Development |
sBLA | supplemental Biologics License Application |
SCCHN | squamous cell carcinoma of the head and neck |
SCLC | small cell lung cancer |
SEC | Securities and Exchange Commission |
SK Biotek | SK Biotek Co., Ltd. |
UK | United Kingdom |
U.S. | United States |
BRISTOL-MYERS SQUIBB COMPANY (REGISTRANT) | ||||
Date: | October 26, 2017 | By: | /s/ Giovanni Caforio | |
Giovanni Caforio Chief Executive Officer | ||||
Date: | October 26, 2017 | By: | /s/ Charles Bancroft | |
Charles Bancroft Chief Financial Officer |
Ratio of Earnings to Fixed Charges: | Nine Months Ended September 30, 2017 | Year Ended December 31, | |||||||||||||||||
2016 | 2015 | 2014 | 2013 | ||||||||||||||||
Dollars in Millions | |||||||||||||||||||
Earnings | |||||||||||||||||||
Earnings from continuing operations before income taxes | $ | 4,433 | $ | 5,915 | $ | 2,077 | $ | 2,381 | $ | 2,891 | |||||||||
Less: | |||||||||||||||||||
Noncontrolling interest in pretax income/(loss) of | |||||||||||||||||||
subsidiaries that have not incurred fixed charges | (66 | ) | 16 | 51 | 38 | 36 | |||||||||||||
Equity in net income of affiliates | 59 | 77 | 83 | 107 | 166 | ||||||||||||||
Capitalized interest | 11 | 10 | 2 | 3 | — | ||||||||||||||
Adjusted Income | 4,429 | 5,812 | 1,941 | 2,233 | 2,689 | ||||||||||||||
Add: | |||||||||||||||||||
Fixed charges | 187 | 226 | 231 | 254 | 255 | ||||||||||||||
Distributed income of equity investments | 74 | 99 | 105 | 153 | 149 | ||||||||||||||
Total Earnings | $ | 4,690 | $ | 6,137 | $ | 2,277 | $ | 2,640 | $ | 3,093 | |||||||||
Fixed Charges | |||||||||||||||||||
Interest expense | $ | 145 | $ | 167 | $ | 184 | $ | 203 | $ | 199 | |||||||||
Capitalized interest | 11 | 10 | 2 | 3 | — | ||||||||||||||
One-third of rental expense(1) | 31 | 49 | 45 | 48 | 56 | ||||||||||||||
Total Fixed Charges | $ | 187 | $ | 226 | $ | 231 | $ | 254 | $ | 255 | |||||||||
Ratio of Earnings to Fixed Charges | 25.08 | 27.15 | 9.86 | 10.39 | 12.13 |
1. | I have reviewed Bristol-Myers Squibb Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017; |
2. | Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report; |
4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined by Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a. | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared; |
b. | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. | evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. | disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; |
5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function): |
a. | all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting, which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
b. | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting. |
/s/ Giovanni Caforio |
Giovanni Caforio Chief Executive Officer |
1. | I have reviewed Bristol-Myers Squibb Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017; |
2. | Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report; |
4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined by Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a. | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared; |
b. | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. | evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. | disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; |
5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function): |
a. | all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting, which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
b. | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting. |
/s/ Charles Bancroft |
Charles Bancroft Chief Financial Officer |
/s/ Giovanni Caforio |
Giovanni Caforio Chief Executive Officer |
/s/ Charles Bancroft |
Charles Bancroft Chief Financial Officer |
Document and Entity Information |
9 Months Ended |
---|---|
Sep. 30, 2017
shares
| |
Document and Entity Information [Abstract] | |
Entity Registrant Name | BRISTOL MYERS SQUIBB CO |
Entity Central Index Key | 0000014272 |
Entity Well-known Seasoned Issuer | Yes |
Entity Current Reporting Status | Yes |
Entity Voluntary Filers | No |
Entity Filer Category | Large Accelerated Filer |
Entity Common Stock, Shares Outstanding | 1,636,699,696 |
Document Type | 10-Q |
Document Period End Date | Sep. 30, 2017 |
Document Fiscal Year Focus | 2017 |
Document Fiscal Period Focus | Q3 |
Current Fiscal Year End Date | --12-31 |
Amendment Flag | false |
CONSOLIDATED STATEMENTS OF EARNINGS (UNAUDITED) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
Sep. 30, 2017 |
Sep. 30, 2016 |
|
Income Statement [Abstract] | ||||
Net product sales | $ 4,862 | $ 4,492 | $ 14,212 | $ 12,888 |
Alliance and other revenues | 392 | 430 | 1,115 | 1,296 |
Total revenues | 5,254 | 4,922 | 15,327 | 14,184 |
Cost of products sold | 1,572 | 1,305 | 4,393 | 3,563 |
Marketing, selling and administrative | 1,147 | 1,144 | 3,388 | 3,450 |
Research and development | 1,543 | 1,138 | 4,490 | 3,540 |
Other (income)/expense | (191) | (224) | (1,377) | (1,198) |
Total Expenses | 4,071 | 3,363 | 10,894 | 9,355 |
Earnings Before Income Taxes | 1,183 | 1,559 | 4,433 | 4,829 |
Provision for Income Taxes | 327 | 344 | 1,129 | 1,220 |
Net Earnings | 856 | 1,215 | 3,304 | 3,609 |
Net Earnings/(Loss) Attributable to Noncontrolling Interest | 11 | 13 | (31) | 46 |
Net Earnings Attributable to BMS | $ 845 | $ 1,202 | $ 3,335 | $ 3,563 |
Earnings per Common Share | ||||
Basic | $ 0.52 | $ 0.72 | $ 2.02 | $ 2.13 |
Diluted | 0.51 | 0.72 | 2.02 | 2.12 |
Cash dividends declared per common share | $ 0.39 | $ 0.38 | $ 1.17 | $ 1.14 |
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
Sep. 30, 2017 |
Sep. 30, 2016 |
|
COMPREHENSIVE INCOME | ||||
Net Earnings | $ 856 | $ 1,215 | $ 3,304 | $ 3,609 |
Other Comprehensive Income/(Loss), net of taxes and reclassifications to earnings [Abstract] | ||||
Derivatives qualifying as cash flow hedges | (1) | 4 | (61) | (126) |
Pension and postretirement benefits | 18 | 72 | 74 | (213) |
Available-for-sale securities | 22 | (8) | 41 | 46 |
Foreign currency translation | 7 | 1 | 28 | 26 |
Other Comprehensive Income/(Loss) | 46 | 69 | 82 | (267) |
Comprehensive Income | 902 | 1,284 | 3,386 | 3,342 |
Comprehensive Income/(Loss) Attributable to Noncontrolling Interest | 11 | 13 | (31) | 46 |
Comprehensive Income Attributable to BMS | $ 891 | $ 1,271 | $ 3,417 | $ 3,296 |
BASIS OF PRESENTATION |
9 Months Ended | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||||||||||||||||
Basis Of Presentation [Text Block] | BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING STANDARDS Bristol-Myers Squibb Company prepared these unaudited consolidated financial statements following the requirements of the SEC and U.S. GAAP for interim reporting. Under those rules, certain footnotes and other financial information that are normally required for annual financial statements can be condensed or omitted. The Company is responsible for the consolidated financial statements included in this Quarterly Report on Form 10-Q, which include all adjustments necessary for a fair presentation of the financial position at September 30, 2017 and December 31, 2016, the results of operations for the three and nine months ended September 30, 2017 and 2016, and cash flows for the nine months ended September 30, 2017 and 2016. All intercompany balances and transactions have been eliminated. These financial statements and the related notes should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2016 included in the 2016 Form 10-K. Refer to the Summary of Abbreviated Terms at the end of this Quarterly Report on Form 10-Q for terms used throughout the document. Revenues, expenses, assets and liabilities can vary during each quarter of the year. Accordingly, the results and trends in these unaudited consolidated financial statements may not be indicative of full year operating results. The preparation of financial statements requires the use of management estimates, judgments and assumptions. The most significant assumptions are estimates used in determining sales rebate and return accruals; legal contingencies; income taxes; determining if an acquisition or divestiture is a business or an asset; and pension and postretirement benefits. Actual results may differ from estimates. Certain prior period amounts were reclassified to conform to the current period presentation. The consolidated statements of cash flows previously presented interest rate swap contract terminations and issuance of common stock as separate line items within cash flows from financing activities which are now presented as components of other financing activities. The reclassifications provide a more concise financial statement presentation and additional information is disclosed in the notes if material. Recently Adopted Accounting Standards Share-based Payment Transactions Amended guidance for share-based payment transactions was adopted in the first quarter of 2017. Net excess tax benefits of $30 million for the nine months ended September 30, 2017 were recognized prospectively as a reduction of tax expense rather than capital in excess of par value of stock. Net excess tax benefits are also presented as an operating cash flow rather than a financing cash flow, and cash payments to tax authorities in connection with shares withheld for statutory tax withholding requirements are presented as a financing cash flow rather than an operating cash flow. The changes in cash flow presentation were applied retrospectively and increased operating cash flows and decreased financing cash flows by $113 million for the nine months ended September 30, 2017 and $193 million for the nine months ended September 30, 2016. Income Tax Accounting for Intra-entity Transfers of Assets Other Than Inventory Amended guidance on income tax accounting for intra-entity transfers of assets other than inventory was early adopted in the first quarter of 2017 on a modified retrospective approach. The amended guidance requires tax consequences of these transfers be recognized in the period the transfer takes place. Net reductions to prepaid and deferred tax assets pertaining to pre-2017 internal transfers of intellectual property of $787 million were adjusted through retained earnings as a cumulative effect of an accounting change which will reduce the annual tax expense by $86 million beginning in 2017. In addition, the tax consequences of additional internal transfers of intellectual property that may occur in the future will be included in income tax expense upon transfer and not amortized in subsequent periods. Recently Issued Accounting Standards Accounting for Hedging Activities In August 2017, the FASB issued amended guidance on derivatives and hedging. The amended guidance revises and expands items eligible for hedge accounting, simplifies hedge effectiveness testing and changes the timing of recognition and presentation for certain hedged items. Certain disclosure requirements are also modified for hedging activities on a prospective basis. The guidance is effective in 2019 with early adoption permitted on a modified retrospective approach. The Company is assessing the potential impact of the new standard. Presentation of Net Periodic Pension and Postretirement Benefits In March 2017, the FASB issued amended guidance requiring all net periodic benefit components for defined benefit pension and other postretirement plans other than service costs to be recorded outside of income from operations (other income). The guidance is effective in 2018 on a retrospective basis. The Company expects that annual cost of products sold; marketing, selling and administrative; and research and development expenses will increase by approximately $130 million in the aggregate with a corresponding offset in other income. Revenue from Contracts with Customers Amended guidance for revenue recognition will be adopted in the first quarter of 2018 using the modified retrospective method with the cumulative effect of the change recognized in retained earnings. The new guidance referred to as ASC 606 requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers and replaces most of the existing revenue recognition standards in U.S. GAAP. A five step model will be utilized to achieve the core principle; (1) identify the customer contract, (2) identify the contract’s performance obligations, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations and (5) recognize revenue when or as a performance obligation is satisfied. The Company’s assessment of the new standard’s impact is substantially complete. The timing of recognizing revenue is not expected to change for typical net product sales to customers, most existing alliance arrangements as well as royalties and sale-based milestones from out-licensing arrangements. In addition, the timing of recognizing royalties, sales-based milestones and other forms of contingent consideration resulting from the divestiture of businesses is not expected to change. However, transaction prices are no longer required to be fixed or determinable and certain variable consideration might be recognized prior to the occurrence or resolution of the contingent event to the extent it is probable that a significant reversal in the amount of estimated cumulative revenue will not occur. Certain estimated future royalties and termination fees for licensing rights previously reacquired by alliance partners are expected to be recognized as contract assets upon adoption of the new standard. Refer to the Sanofi and Erbitux* Japan arrangements in "Note 3. Alliances" of the 2016 Form 10-K. As a result of the new guidance and cumulative effect adjustment, revenue and other income is expected to be lower in 2018 by approximately $225 million and $125 million, respectively, compared to what would have been reported under the previous standard. In addition to the items discussed above, the following recently issued accounting standards have not been adopted. Refer to the 2016 Form 10-K for additional information and their potential impacts.
|
BUSINESS SEGMENT INFORMATION |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Segment Information [Text Block] | BUSINESS SEGMENT INFORMATION BMS operates in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. A global research and development organization and supply chain organization are responsible for the discovery, development, manufacturing and supply of products. Regional commercial organizations market, distribute and sell the products. The business is also supported by global corporate staff functions. The determination of a single segment is consistent with the financial information regularly reviewed by the chief executive officer for purposes of evaluating performance, allocating resources, setting incentive compensation targets and planning and forecasting future periods. Product revenues and the composition of total revenues were as follows:
|
ALLIANCES |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Alliances [Text Block] | ALLIANCES BMS enters into collaboration arrangements with third parties for the development and commercialization of certain products. Although each of these arrangements is unique in nature, both parties are active participants in the operating activities of the collaboration and are exposed to significant risks and rewards depending on the commercial success of the activities. BMS may either in-license intellectual property owned by the other party or out-license its intellectual property to the other party. These arrangements also typically include research, development, manufacturing and/or commercial activities and can cover a single investigational compound or commercial product or multiple compounds and/or products in various life cycle stages. The rights and obligations of the parties can be global or limited to geographic regions. We refer to these collaborations as alliances and our partners as alliance partners. Products sold through alliance arrangements in certain markets include Opdivo, Eliquis, Orencia, Sprycel, Yervoy, Empliciti, Sustiva (Atripla*) and certain other brands. Selected financial information pertaining to our alliances was as follows, including net product sales when BMS is the principal in the third-party customer sale for products subject to the alliance. Expenses summarized below do not include all amounts attributed to the activities for the products in the alliance, but only the payments between the alliance partners or the related amortization if the payments were deferred or capitalized.
Specific information pertaining to each of our significant alliances is discussed in our 2016 Form 10-K, including their nature and purpose, the significant rights and obligations of the parties and specific accounting policy elections. Significant developments and updates related to alliances during the nine months ended September 30, 2017 are set forth below. AstraZeneca BMS received $100 million from AstraZeneca as additional contingent consideration for the diabetes business divestiture upon achievement of a regulatory approval milestone in the first quarter of 2017 (included in other income). F-Star Alpha In the first quarter of 2017, BMS discontinued development of FS102 (an anti-HER2 antibody fragment) which was in Phase I development for the treatment of breast and gastric cancer. BMS will not exercise its option to purchase F-Star Alpha which was previously consolidated by BMS as a variable interest entity. As a result, an IPRD charge of $75 million was included in R&D expense and attributed to noncontrolling interest in the first quarter of 2017. |
ACQUISITIONS, DIVESTITURES AND LICENSING ARRANGEMENTS |
9 Months Ended |
---|---|
Sep. 30, 2017 | |
Acquisitions, Divestitures and Licensing Arrangements [Abstract] | |
Acquisitions, Divestitures and Licensing Arrangements [Text Block] | ACQUISITIONS, DIVESTITURES AND LICENSING ARRANGEMENTS Acquisitions IFM In the third quarter of 2017, BMS acquired all of the outstanding shares of IFM, a private biotechnology company focused on developing therapies that modulate novel targets in the innate immune system to treat cancer, autoimmunity and inflammatory diseases. The acquisition provides BMS with full rights to IFM's preclinical STING and NLRP3 agonist programs focused on enhancing the innate immune response for treating cancer. The consideration includes an upfront payment of $300 million and contingent development, regulatory and sales-based milestone payments of up to $1.0 billion for the first product from each of the two programs and additional contingent milestone payments of up to $555 million for any subsequent products from these programs. No significant IFM processes were acquired, therefore the transaction was accounted for as an asset acquisition because IFM was determined not to be a business as that term is defined in ASC 805 - Business Combinations. BMS also paid $25 million for certain negotiation rights to collaborate, license or acquire an NLRP3 antagonist program from a newly formed entity established by the former shareholders of IFM. The transactions resulted in $310 million of R&D expense and $15 million of deferred tax assets for net operating losses and tax credit carryforwards. Flexus In the second quarter of 2017, a $100 million milestone was achieved and paid to former stockholders of Flexus as additional contingent consideration following the commencement of a Phase II clinical study of an anti-cancer IDO inhibitor. The additional consideration was included in R&D expense as the Flexus acquisition in 2015 was accounted for as an asset acquisition. Cardioxyl In the second quarter of 2017, a $100 million milestone was achieved and paid to former stockholders of Cardioxyl as additional contingent consideration following the commencement of a Phase II clinical study of a cardiovascular Nitroxyl Donor. The additional consideration was included in R&D expense as the Cardioxyl acquisition in 2015 was accounted for as an asset acquisition. Divestitures SK Biotek In the second quarter of 2017, BMS agreed to sell its small molecule active pharmaceutical ingredient manufacturing operations in Swords, Ireland to SK Biotek. The divestiture includes the transfer of the facility, the majority of employees at the site, inventories and certain third-party contract manufacturing obligations. The purchase price is expected to be approximately $140 million subject to inventory levels on the date of closing. The transaction is expected to close in the fourth quarter of 2017 subject to SK Biotek's receipt of certain environmental permits and other customary closing conditions and will be accounted for as a sale of a business. Net assets of approximately $140 million were accounted for as held-for-sale as of September 30, 2017, consisting primarily of inventories and property, plant and equipment, and were included in prepaid expenses and other. The assets were reduced to their estimated relative fair value after considering the purchase price resulting in an impairment charge of $128 million that was included in cost of products sold in the nine months ended September 30, 2017. SK Biotek will provide certain manufacturing services for BMS through 2022. Revenues and pretax earnings related to this operation were not material in 2017 and 2016 (excluding the impairment charge). Licensing Arrangements Halozyme In the third quarter of 2017, BMS and Halozyme announced a global collaboration and license agreement to develop subcutaneously administered BMS IO medicines using Halozyme's ENHANZE* drug-delivery technology. This technology may allow for more rapid delivery of large volume injectable medications, such as medications that are currently delivered intravenously, through subcutaneous delivery. BMS agreed to pay $105 million to Halozyme for access to the technology which will be included in R&D expense in the fourth quarter of 2017. BMS has designated multiple IO targets, including PD-1, to develop using the ENHANZE* technology and has an option to select additional targets within five years from the effective date up to a maximum of 11 targets. BMS may pay up to $160 million upon achievement of contingent development, regulatory and sales-based milestone events for each of the nominated collaboration targets, additional milestone payments for combination products and future royalties on sales of products using the ENHANZE* technology. The agreement is subject to obtaining customary regulatory and antitrust approvals. CytomX In the second quarter of 2017, BMS expanded its strategic collaboration with CytomX to discover novel therapies using CytomX’s proprietary Probody platform. As part of the original May 2014 collaboration to discover, develop and commercialize Probody therapeutics, BMS selected four oncology targets, including CTLA-4. Pursuant to the expanded agreement, CytomX will grant BMS exclusive worldwide rights to develop and commercialize Probody therapeutics for up to eight additional targets. BMS paid CytomX $75 million for the rights to the initial four targets which was expensed as R&D prior to 2017. BMS paid $200 million to CytomX for access to the additional targets which was included in R&D expense in the second quarter of 2017. BMS will also reimburse CytomX for certain research costs over the collaboration period, pay up to $448 million upon achievement of contingent development, regulatory and sales milestone events for each collaboration target and future royalties if a product is approved and commercialized. Biogen In the second quarter of 2017, BMS out-licensed to Biogen exclusive rights to develop and commercialize BMS-986168, an anti-eTau compound in development for Progressive Supranuclear Palsy. Biogen paid $300 million to BMS which was included in other income in the second quarter of 2017 as BMS has no further performance obligations as part of the agreement. BMS is also entitled to contingent development, regulatory and sales based milestone payments of up to $410 million if achieved as well as future royalties if the product is ultimately approved and commercialized. BMS originally acquired the rights to this compound in 2014 through its acquisition of iPierian. Biogen assumed all of BMS’s remaining obligations to the former stockholders of iPierian. Roche In the second quarter of 2017, BMS out-licensed to Roche exclusive rights to develop and commercialize BMS-986089, an anti-myostatin adnectin in development for Duchenne Muscular Dystrophy. Roche paid $170 million to BMS which was included in other income in the second quarter of 2017 as BMS has no further performance obligations as part of the agreement. BMS will also be entitled to contingent development and regulatory milestone payments of up to $205 million if achieved and future royalties if the product is ultimately approved and commercialized. |
OTHER (INCOME)/EXPENSE |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Nonoperating Income (Expense) [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other (Income)/Expense [Text Block] | OTHER (INCOME)/EXPENSE
|
RESTRUCTURING |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring Charges [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring and Related Activities Disclosure [Text Block] | RESTRUCTURING In October 2016, the Company announced a restructuring plan to evolve and streamline its operating model and expects to incur charges in connection with employee workforce reductions and early site exits. The majority of the charges are expected to be incurred through 2020, range between $1.5 billion to $2.0 billion and consist of employee termination benefit costs, contract termination costs, plant and equipment accelerated depreciation and impairment charges and other site shutdown costs. Cash outlays in connection with these actions are expected to be approximately 40% to 50% of the total charges. Charges of $631 million have been recognized for these actions since the announcement ($82 million and $534 million for the three and nine months ended September 30, 2017, respectively). These charges include an impairment charge for the manufacturing operations in Swords, Ireland discussed in "—Note 4. Acquisitions, Divestitures and Licensing Arrangements." Restructuring charges are recognized upon meeting certain criteria, including finalization of committed plans, reliable estimates and discussions with local works councils in certain markets. Other restructuring charges recognized prior to the above actions were primarily related to specialty care transformation initiatives designed to create a more simplified organization across all functions and geographic markets. In addition, accelerated depreciation and other charges were incurred in connection with the expected early exits of a manufacturing site in Ireland and R&D site in the U.S. Employee workforce reductions were approximately 1,200 and 500 for the nine months ended September 30, 2017 and 2016, respectively, across all geographic regions for manufacturing, marketing, selling, administrative and R&D personnel. The following tables summarize the charges and activity related to the restructuring actions:
|
INCOME TAXES |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income Tax Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income Tax Disclosure [Text Block] | INCOME TAXES
The effective tax rate is lower than the U.S. statutory rate of 35% which is primarily attributable to undistributed earnings of certain foreign subsidiaries in low tax jurisdictions that have been considered or are expected to be indefinitely reinvested offshore. These undistributed earnings primarily relate to operations in Switzerland, Ireland and Puerto Rico. If these undistributed earnings are repatriated to the U.S. in the future, or if it were determined that such earnings are to be remitted in the foreseeable future, additional tax provisions would be required. Due to complexities in the tax laws and assumptions that would have to be made, it is not practicable to estimate the amounts of income taxes that would have to be provided. Reforms to U.S. tax laws related to foreign earnings have been proposed and if adopted, may increase taxes, which could reduce the results of operations and cash flows. BMS operates under a favorable tax grant in Puerto Rico not scheduled to expire prior to 2023. Jurisdictional tax rates and other tax impacts attributed to R&D charges, divestiture transactions and other discrete pretax items increased the effective tax rate by 3.7% and 3.1% in the nine months ended September 30, 2017 and 2016, respectively, including non-deductible R&D asset acquisition charges and goodwill allocated to business divestitures. The tax impact for discrete items are reflected immediately and are not considered in estimating the annual effective tax rate. The adoption of the amended guidance for intra-entity transfers of assets other than inventory and share-based payment transactions reduced the effective tax rate by 2.1% in the nine months ended September 30, 2017. Refer to "—Note 1. Basis of Presentation and Recently Issued Accounting Standards" for additional information. BMS is currently under examination by a number of tax authorities which have proposed or are considering proposing material adjustments to tax positions for issues such as transfer pricing, certain tax credits and the deductibility of certain expenses. It is reasonably possible that new issues will be raised by tax authorities which may require adjustments to the amount of unrecognized tax benefits; however, an estimate of such adjustments cannot reasonably be made at this time. It is also reasonably possible that the total amount of unrecognized tax benefits at September 30, 2017 could decrease in the range of approximately $255 million to $315 million in the next twelve months as a result of the settlement of certain tax audits and other events. The expected change in unrecognized tax benefits may result in the payment of additional taxes, adjustment of certain deferred taxes and/or recognition of tax benefits. |
EARNINGS PER SHARE |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Text Block] | EARNINGS PER SHARE
|
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investments, Debt and Equity Securities [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Instruments [Text Block] | FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Financial assets and liabilities measured at fair value on a recurring basis are summarized below:
As further described in "Note 9. Financial Instruments and Fair Value Measurements" in our 2016 Form 10-K, our fair value estimates use inputs that are either (1) quoted prices for identical assets or liabilities in active markets (Level 1 inputs), (2) observable prices for similar assets or liabilities in active markets or for identical or similar assets or liabilities in markets that are not active (Level 2 inputs) or (3) unobservable inputs (Level 3 inputs). There were no Level 3 financial assets or liabilities as of September 30, 2017 and December 31, 2016. Available-for-sale Securities The following table summarizes available-for-sale securities:
Qualifying Hedges and Non-Qualifying Derivatives The following table summarizes the fair value of outstanding derivatives:
Cash Flow Hedges — The notional amount of outstanding foreign currency forward contracts was primarily attributed to the euro ($2.2 billion) and Japanese yen ($586 million) at September 30, 2017. BMS terminated forward starting interest rate swap contracts in the first quarter of 2017 with an aggregate notional value of $750 million. The proceeds and related gain were not material. Net Investment Hedges — Non-U.S. dollar borrowings of €950 million ($1.1 billion) are designated to hedge euro currency exposures of the net investment in certain foreign affiliates. Fair Value Hedges — The notional amount of fixed-to-floating interest rate swap contracts terminated was $500 million in 2016 generating proceeds of $43 million (including accrued interest). Debt Obligations Short-term debt obligations include:
The average amount of commercial paper outstanding was $211 million at a weighted-average rate of 1.12% during 2017. The maximum amount of commercial paper outstanding was $1.0 billion with $799 million outstanding at September 30, 2017. Long-term debt and the current portion of long-term debt include:
The fair value of debt was $7.4 billion at September 30, 2017 and $6.9 billion at December 31, 2016 valued using Level 2 inputs. Interest payments were $172 million and $140 million for the nine months ended September 30, 2017 and 2016, respectively, net of amounts related to interest rate swap contracts. On February 27, 2017, BMS issued senior unsecured notes in a registered public offering. The notes rank equally in right of payment with all of BMS's existing and future senior unsecured indebtedness. BMS may redeem the notes, in whole or in part, at any time prior to maturity at a predetermined redemption price. The following table summarizes the note issuances:
During the third quarter of 2017, $750 million of 0.875% Notes matured and were repaid. During the second quarter of 2017, the Company repurchased certain long-term debt obligations with interest rates ranging from 5.875% to 6.875%. The following summarizes the debt repurchase activity:
|
RECEIVABLES |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounts Receivable, Net [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Receivables [Text Block] | RECEIVABLES
Non-U.S. receivables sold on a nonrecourse basis were $460 million and $470 million for the nine months ended September 30, 2017 and 2016, respectively. Receivables from our three largest pharmaceutical wholesalers in the U.S. represented 64% and 66% of total trade receivables at September 30, 2017 and December 31, 2016, respectively. |
INVENTORIES |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory, Net [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventories [Text Block] | INVENTORIES
Inventories of $120 million are included in assets held-for-sale as of September 30, 2017 due to the expected transfer of manufacturing operations in Swords, Ireland to SK Biotek. Refer to "—Note 4. Acquisitions, Divestitures and Licensing Arrangements" for additional information. Other assets include inventory expected to remain on hand beyond one year in both periods and inventory pending regulatory approval of $54 million at December 31, 2016. |
PROPERTY, PLANT AND EQUIPMENT |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property, Plant and Equipment [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property, Plant and Equipment [Text Block] | PROPERTY, PLANT AND EQUIPMENT
Depreciation expense was $509 million and $319 million for the nine months ended September 30, 2017 and 2016, respectively. Refer to "—Note 4. Acquisitions, Divestitures and Licensing Arrangements" for additional information relating to the expected transfer of manufacturing operations in Swords, Ireland to SK Biotek. |
OTHER INTANGIBLE ASSETS |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Text Block] | OTHER INTANGIBLE ASSETS
Amortization expense was $142 million and $134 million for the nine months ended September 30, 2017 and 2016, respectively. |
ACCRUED LIABILITIES |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payables and Accruals [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | ACCRUED LIABILITIES
|
EQUITY |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders' Equity Note Disclosure [Text Block] | EQUITY
BMS has a stock repurchase program authorized by its Board of Directors allowing for repurchases in the open market or through private transactions, including plans established in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. The stock repurchase program does not have an expiration date and may be suspended or discontinued at any time. Treasury stock is recognized at the cost to reacquire the shares. Shares issued from treasury are recognized utilizing the first-in first-out method. BMS repurchased approximately 3.8 million shares for $226 million during the three months ended September 30, 2017. In February 2017, BMS executed accelerated share repurchase agreements to repurchase an aggregate $2 billion of common stock. The agreements were funded through a combination of debt and cash. In February 2017, an initial delivery of approximately 28.7 million shares of BMS common stock, representing approximately 80% of the notional amount of the agreements, was received by BMS and included in treasury stock. Upon settlement of the accelerated share repurchase agreements in May 2017, BMS received an additional 7.8 million shares determined using the volume-weighted average price of BMS common stock during the term of the transaction. The components of other comprehensive income/(loss) were as follows:
The accumulated balances related to each component of other comprehensive loss, net of taxes, were as follows:
|
PENSION AND POSTRETIREMENT BENEFIT PLANS |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Compensation and Retirement Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pension and Other Postretirement Benefits [Text Block] | PENSION AND POSTRETIREMENT BENEFIT PLANS The net periodic benefit cost/(credit) of defined benefit pension plans includes:
Pension settlement charges were recognized after determining that the annual lump sum payments will likely exceed the annual interest and service costs for the primary and certain other U.S. pension plans. The charges included the acceleration of a portion of unrecognized actuarial losses. Non-current pension liabilities were $477 million at September 30, 2017 and $600 million at December 31, 2016. Defined contribution plan expense in the U.S. was $46 million and $49 million for the three months ended September 30, 2017 and 2016, respectively, and $142 million and $141 million for the nine months ended September 30, 2017 and 2016, respectively. |
LEGAL PROCEEDINGS AND CONTINGENCIES |
9 Months Ended |
---|---|
Sep. 30, 2017 | |
Commitments and Contingencies Disclosure [Abstract] | |
Legal Proceedings and Contingencies [Text Block] | LEGAL PROCEEDINGS AND CONTINGENCIES The Company and certain of its subsidiaries are involved in various lawsuits, claims, government investigations and other legal proceedings that arise in the ordinary course of business. These claims or proceedings can involve various types of parties, including governments, competitors, customers, suppliers, service providers, licensees, employees, or shareholders, among others. The resolution of these matters often develops over a long period of time and expectations can change as a result of new findings, rulings, appeals or settlement arrangements. The Company recognizes accruals for such contingencies when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. These matters involve patent infringement, antitrust, securities, pricing, sales and marketing practices, environmental, commercial, contractual rights, licensing obligations, health and safety matters, consumer fraud, employment matters, product liability and insurance coverage. Legal proceedings that are material or that the Company believes could become material are described below. Although the Company believes it has substantial defenses in these matters, there can be no assurance that there will not be an increase in the scope of pending matters or that any future lawsuits, claims, government investigations or other legal proceedings will not be material. Unless otherwise noted, the Company is unable to assess the outcome of the respective litigation nor is it able to provide an estimated range of potential loss. Furthermore, failure to enforce our patent rights would likely result in substantial decreases in the respective product revenues from generic competition. INTELLECTUAL PROPERTY Plavix* — Australia As previously disclosed, Sanofi was notified that, in August 2007, GenRx Proprietary Limited (GenRx) obtained regulatory approval of an application for clopidogrel bisulfate 75mg tablets in Australia. GenRx, formerly a subsidiary of Apotex Inc. (Apotex), has since changed its name to Apotex. In August 2007, Apotex filed an application in the Federal Court of Australia (the Federal Court) seeking revocation of Sanofi’s Australian Patent No. 597784 (Case No. NSD 1639 of 2007). Sanofi filed counterclaims of infringement and sought an injunction. On September 21, 2007, the Federal Court granted Sanofi’s injunction. A subsidiary of the Company was subsequently added as a party to the proceedings. In February 2008, a second company, Spirit Pharmaceuticals Pty. Ltd., also filed a revocation suit against the same patent. This case was consolidated with the Apotex case, and a trial occurred in April 2008. On August 12, 2008, the Federal Court of Australia held that claims of Patent No. 597784 covering clopidogrel bisulfate, hydrochloride, hydrobromide, and taurocholate salts were valid. The Federal Court also held that the process claims, pharmaceutical composition claims, and claim directed to clopidogrel and its pharmaceutically acceptable salts were invalid. The Company and Sanofi filed notices of appeal in the Full Court of the Federal Court of Australia (Full Court) appealing the holding of invalidity of the claim covering clopidogrel and its pharmaceutically acceptable salts, process claims, and pharmaceutical composition claims which have stayed the Federal Court’s ruling. Apotex filed a notice of appeal appealing the holding of validity of the clopidogrel bisulfate, hydrochloride, hydrobromide, and taurocholate claims. A hearing on the appeals occurred in February 2009. On September 29, 2009, the Full Court held all of the claims of Patent No. 597784 invalid. In November 2009, the Company and Sanofi applied to the High Court of Australia (High Court) for special leave to appeal the judgment of the Full Court. In March 2010, the High Court denied the Company and Sanofi’s request to hear the appeal of the Full Court decision. The case has been remanded to the Federal Court for further proceedings related to damages sought by Apotex. The Australian government has intervened in this matter and is also seeking damages for alleged losses experienced during the period when the injunction was in place. The Company and Apotex have settled the Apotex case, and the case has been dismissed. The Australian government's claim is still pending and a trial was concluded in September 2017. The Company is expecting a decision in 2018. It is not possible at this time to predict the outcome of the Australian government’s claim or its impact on the Company. Sprycel - European Union In May 2013, Apotex, Actavis Group PTC ehf, Generics [UK] Limited (Mylan) and an unnamed company filed oppositions in the EPO seeking revocation of European Patent No. 1169038 (the ‘038 patent) covering dasatinib, the active ingredient in Sprycel. The ‘038 patent is scheduled to expire in April 2020 (excluding potential term extensions). On January 20, 2016, the Opposition Division of the EPO revoked the ‘038 patent. In May 2016, the Company appealed the EPO’s decision to the EPO Board of Appeal. In February 2017, the EPO Board of Appeal upheld the Opposition Division's decision, and revoked the ‘038 patent. Orphan drug exclusivity and data exclusivity for Sprycel in the EU expired in November 2016. The EPO Board of Appeal's decision does not affect the validity of our other Sprycel patents within and outside Europe, including different patents that cover the monohydrate form of dasatinib and the use of dasatinib to treat CML. Additionally, in February 2017, the EPO Board of Appeal reversed and remanded an invalidity decision on European Patent No. 1610780 and its claim to the use of dasatinib to treat CML, which the EPO's Opposition Division had revoked in October 2012. The Company intends to take appropriate legal actions to protect Sprycel. We may experience a decline in European revenues in the event that generic dasatinib product enters the market. Anti-PD-1 Antibody Patent Oppositions and Litigation In September 2015, Dana-Farber Cancer Institute (Dana-Farber) filed a complaint in Massachusetts federal court seeking to correct the inventorship of five related U.S. patents directed to methods of treating cancer using PD-1 and PD-L1 antibodies. Specifically, Dana-Farber is seeking to add two scientists as inventors to these patents. In September 2017, Pfizer filed a motion seeking to intervene in this case alleging that one of the scientists identified by Dana-Farber was employed by a company eventually acquired by Pfizer. This motion has not been acted upon by the court. Eliquis Patent Litigation In February, March and April 2017, twenty-five generic companies sent the Company Paragraph-IV certification letters informing the Company that they had filed abbreviated new drug applications (ANDAs) seeking approval of generic versions of Eliquis. As a result, two Eliquis patents listed in the FDA Orange Book have now been challenged: the composition of matter patent claiming apixaban specifically and a formulation patent. In April 2017, the Company, along with its partner Pfizer, initiated patent lawsuits under the Hatch-Waxman Act against all generic filers in federal district courts in Delaware and West Virginia. In August 2017, the United States Patent and Trademark Office granted patent term restoration to the composition of matter patent, thereby restoring the term of the Eliquis composition of matter patent, which is the Company’s basis for projected loss of exclusivity, from February 2023 to November 2026. In September 2017, the Company settled its lawsuit with Teva Pharmaceuticals USA, Inc. and the parties agreed to dismiss the case. The settlement does not impact the Company’s projected loss of exclusivity for Eliquis. PRICING, SALES AND PROMOTIONAL PRACTICES LITIGATION Plavix* State Attorneys General Lawsuits The Company and certain affiliates of Sanofi are defendants in consumer protection and/or false advertising actions brought by several states relating to the sales and promotion of Plavix*. It is not possible at this time to reasonably assess the outcome of these lawsuits or their potential impact on the Company. PRODUCT LIABILITY LITIGATION The Company is a party to various product liability lawsuits. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. As previously disclosed, in addition to lawsuits, the Company also faces unfiled claims involving its products. Plavix* As previously disclosed, the Company and certain affiliates of Sanofi are defendants in a number of individual lawsuits in various state and federal courts claiming personal injury damage allegedly sustained after using Plavix*. Over 5,000 claims involving injury plaintiffs as well as claims by spouses and/or other beneficiaries, have been filed in state and federal courts in various states including California, New Jersey, Delaware and New York. In February 2013, the Judicial Panel on Multidistrict Litigation granted the Company and Sanofi’s motion to establish a multi-district litigation (MDL) to coordinate Federal pretrial proceedings in Plavix* product liability and related cases in New Jersey Federal Court. Following the United States Supreme Court’s June 2017 reversal of a California Supreme Court decision that had held that the California state courts can exercise personal jurisdiction over the claims of non-California residents, over 2,000 out-of-state resident plaintiffs' claims (including spouses and beneficiaries) previously pending in the California state court have been, or are in the process of being dismissed. Some number of these California non-resident plaintiffs’ claims may be re-filed in federal court. It is not possible at this time to reasonably assess the outcome of these lawsuits or the potential impact on the Company. Byetta* Amylin, a former subsidiary of the Company, and Lilly are co-defendants in product liability litigation related to Byetta*. To date, there are over 500 separate lawsuits pending on behalf of approximately 2,000 active plaintiffs (including pending settlements), which include injury plaintiffs as well as claims by spouses and/or other beneficiaries, in various courts in the U.S. The Company has agreed in principle to resolve over 15 of these claims. The majority of these cases have been brought by individuals who allege personal injury sustained after using Byetta*, primarily pancreatic cancer and pancreatitis, and, in some cases, claiming alleged wrongful death. The majority of cases were pending in Federal Court in San Diego in an MDL or in a coordinated proceeding in California Superior Court in Los Angeles (JCCP). In November 2015, the defendants' motion for summary judgment based on federal preemption was granted in both the MDL and the JCCP. The plaintiffs in the MDL have appealed to the U.S. Court of Appeals for the Ninth Circuit and the JCCP plaintiffs have appealed to the California Court of Appeal. Amylin has product liability insurance covering a substantial number of claims involving Byetta* and any additional liability to Amylin with respect to Byetta* is expected to be shared between the Company and AstraZeneca. It is not possible to reasonably predict the outcome of any lawsuit, claim or proceeding or the potential impact on the Company. Abilify* The Company and Otsuka are co-defendants in product liability litigation related to Abilify*. Plaintiffs allege Abilify* caused them to engage in compulsive gambling and other impulse control disorders. There have been over 400 cases filed in state and federal courts and several additional cases are pending in Canada. The Judicial Panel on Multidistrict Litigation has consolidated the federal court cases for pretrial purposes in the United States District Court for the Northern District of Florida. Eliquis The Company and Pfizer are co-defendants in product liability litigation related to Eliquis. Plaintiffs assert claims, including claims for wrongful death, as a result of bleeding they allege was caused by their use of Eliquis. The majority of these claims are pending in an MDL in the United States District Court for the Southern District of New York and in state court in Delaware. As of October 2017, there are over 150 cases pending in the MDL and state courts in the United States and one pending in Canada. Over 80 cases have been dismissed with prejudice by the MDL. Plaintiffs have appealed some of the dismissed cases to the Second Circuit Court of Appeals. SHAREHOLDER DERIVATIVE LITIGATION Since December 2015, three shareholder derivative lawsuits were filed in New York state court against certain officers and directors of the Company. The plaintiffs allege, among other things, breaches of fiduciary duty surrounding the Company’s previously disclosed October 2015 civil settlement with the Securities and Exchange Commission of alleged Foreign Corrupt Practices Act violations in China in which the Company agreed to a payment of approximately $14.7 million in disgorgement, penalties and interest. As of October 2017, all three of the lawsuits have been dismissed. The Company received a notice of appeal for one of the lawsuits in September 2017. GOVERNMENT INVESTIGATIONS Like other pharmaceutical companies, the Company and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which BMS operates. As a result, the Company, from time to time, is subject to various governmental inquiries and investigations. It is possible that criminal charges, substantial fines and/or civil penalties, could result from government investigations. ENVIRONMENTAL PROCEEDINGS As previously reported, the Company is a party to several environmental proceedings and other matters, and is responsible under various state, federal and foreign laws, including CERCLA, for certain costs of investigating and/or remediating contamination resulting from past industrial activity at the Company’s current or former sites or at waste disposal or reprocessing facilities operated by third parties. CERCLA Matters With respect to CERCLA matters for which the Company is responsible under various state, federal and foreign laws, the Company typically estimates potential costs based on information obtained from the U.S. Environmental Protection Agency, or counterpart state or foreign agency and/or studies prepared by independent consultants, including the total estimated costs for the site and the expected cost-sharing, if any, with other “potentially responsible parties,” and the Company accrues liabilities when they are probable and reasonably estimable. The Company estimated its share of future costs for these sites to be $63 million at September 30, 2017, which represents the sum of best estimates or, where no best estimate can reasonably be made, estimates of the minimal probable amount among a range of such costs (without taking into account any potential recoveries from other parties). The amount includes the estimated costs for any additional probable loss associated with the previously disclosed North Brunswick Township High School Remediation Site. |
BASIS OF PRESENTATION (Policies) |
9 Months Ended | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||||||||||||||||
Nature of Business | Bristol-Myers Squibb Company prepared these unaudited consolidated financial statements following the requirements of the SEC and U.S. GAAP for interim reporting. Under those rules, certain footnotes and other financial information that are normally required for annual financial statements can be condensed or omitted. The Company is responsible for the consolidated financial statements included in this Quarterly Report on Form 10-Q, which include all adjustments necessary for a fair presentation of the financial position at September 30, 2017 and December 31, 2016, the results of operations for the three and nine months ended September 30, 2017 and 2016, and cash flows for the nine months ended September 30, 2017 and 2016. All intercompany balances and transactions have been eliminated. These financial statements and the related notes should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2016 included in the 2016 Form 10-K. Refer to the Summary of Abbreviated Terms at the end of this Quarterly Report on Form 10-Q for terms used throughout the document. |
||||||||||||||||
Use of Estimates | Revenues, expenses, assets and liabilities can vary during each quarter of the year. Accordingly, the results and trends in these unaudited consolidated financial statements may not be indicative of full year operating results. The preparation of financial statements requires the use of management estimates, judgments and assumptions. The most significant assumptions are estimates used in determining sales rebate and return accruals; legal contingencies; income taxes; determining if an acquisition or divestiture is a business or an asset; and pension and postretirement benefits. Actual results may differ from estimates. |
||||||||||||||||
Reclassifications | Certain prior period amounts were reclassified to conform to the current period presentation. The consolidated statements of cash flows previously presented interest rate swap contract terminations and issuance of common stock as separate line items within cash flows from financing activities which are now presented as components of other financing activities. The reclassifications provide a more concise financial statement presentation and additional information is disclosed in the notes if material. |
||||||||||||||||
New Accounting Pronouncements | Recently Adopted Accounting Standards Share-based Payment Transactions Amended guidance for share-based payment transactions was adopted in the first quarter of 2017. Net excess tax benefits of $30 million for the nine months ended September 30, 2017 were recognized prospectively as a reduction of tax expense rather than capital in excess of par value of stock. Net excess tax benefits are also presented as an operating cash flow rather than a financing cash flow, and cash payments to tax authorities in connection with shares withheld for statutory tax withholding requirements are presented as a financing cash flow rather than an operating cash flow. The changes in cash flow presentation were applied retrospectively and increased operating cash flows and decreased financing cash flows by $113 million for the nine months ended September 30, 2017 and $193 million for the nine months ended September 30, 2016. Income Tax Accounting for Intra-entity Transfers of Assets Other Than Inventory Amended guidance on income tax accounting for intra-entity transfers of assets other than inventory was early adopted in the first quarter of 2017 on a modified retrospective approach. The amended guidance requires tax consequences of these transfers be recognized in the period the transfer takes place. Net reductions to prepaid and deferred tax assets pertaining to pre-2017 internal transfers of intellectual property of $787 million were adjusted through retained earnings as a cumulative effect of an accounting change which will reduce the annual tax expense by $86 million beginning in 2017. In addition, the tax consequences of additional internal transfers of intellectual property that may occur in the future will be included in income tax expense upon transfer and not amortized in subsequent periods. Recently Issued Accounting Standards Accounting for Hedging Activities In August 2017, the FASB issued amended guidance on derivatives and hedging. The amended guidance revises and expands items eligible for hedge accounting, simplifies hedge effectiveness testing and changes the timing of recognition and presentation for certain hedged items. Certain disclosure requirements are also modified for hedging activities on a prospective basis. The guidance is effective in 2019 with early adoption permitted on a modified retrospective approach. The Company is assessing the potential impact of the new standard. Presentation of Net Periodic Pension and Postretirement Benefits In March 2017, the FASB issued amended guidance requiring all net periodic benefit components for defined benefit pension and other postretirement plans other than service costs to be recorded outside of income from operations (other income). The guidance is effective in 2018 on a retrospective basis. The Company expects that annual cost of products sold; marketing, selling and administrative; and research and development expenses will increase by approximately $130 million in the aggregate with a corresponding offset in other income. Revenue from Contracts with Customers Amended guidance for revenue recognition will be adopted in the first quarter of 2018 using the modified retrospective method with the cumulative effect of the change recognized in retained earnings. The new guidance referred to as ASC 606 requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers and replaces most of the existing revenue recognition standards in U.S. GAAP. A five step model will be utilized to achieve the core principle; (1) identify the customer contract, (2) identify the contract’s performance obligations, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations and (5) recognize revenue when or as a performance obligation is satisfied. The Company’s assessment of the new standard’s impact is substantially complete. The timing of recognizing revenue is not expected to change for typical net product sales to customers, most existing alliance arrangements as well as royalties and sale-based milestones from out-licensing arrangements. In addition, the timing of recognizing royalties, sales-based milestones and other forms of contingent consideration resulting from the divestiture of businesses is not expected to change. However, transaction prices are no longer required to be fixed or determinable and certain variable consideration might be recognized prior to the occurrence or resolution of the contingent event to the extent it is probable that a significant reversal in the amount of estimated cumulative revenue will not occur. Certain estimated future royalties and termination fees for licensing rights previously reacquired by alliance partners are expected to be recognized as contract assets upon adoption of the new standard. Refer to the Sanofi and Erbitux* Japan arrangements in "Note 3. Alliances" of the 2016 Form 10-K. As a result of the new guidance and cumulative effect adjustment, revenue and other income is expected to be lower in 2018 by approximately $225 million and $125 million, respectively, compared to what would have been reported under the previous standard. In addition to the items discussed above, the following recently issued accounting standards have not been adopted. Refer to the 2016 Form 10-K for additional information and their potential impacts.
|
BUSINESS SEGMENT INFORMATION (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Product Revenues [Table Text Block] | Product revenues and the composition of total revenues were as follows:
|
ALLIANCES (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Alliance Arrangements [Table Text Block] | Selected financial information pertaining to our alliances was as follows, including net product sales when BMS is the principal in the third-party customer sale for products subject to the alliance. Expenses summarized below do not include all amounts attributed to the activities for the products in the alliance, but only the payments between the alliance partners or the related amortization if the payments were deferred or capitalized.
|
OTHER (INCOME)/EXPENSE (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Nonoperating Income (Expense) [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule Of Other Income Expense [Table Text Block] |
|
RESTRUCTURING (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring Cost and Reserve [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring and Related Costs [Table Text Block] | The following tables summarize the charges and activity related to the restructuring actions:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Restructuring Reserve by Type of Cost [Table Text Block] |
|
INCOME TAXES (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income Tax Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Provision for Income Taxes [Table Text Block] |
|
EARNINGS PER SHARE (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] |
|
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investments, Debt and Equity Securities [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] | Financial assets and liabilities measured at fair value on a recurring basis are summarized below:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Available-for-sale Securities [Table Text Block] | The following table summarizes available-for-sale securities:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Derivatives and Fair Value [Table Text Block] | The following table summarizes the fair value of outstanding derivatives:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Short-term Debt [Table Text Block] | Short-term debt obligations include:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Fair Value and Other Adjustments to Long Term Debt [Table Text Block] | Long-term debt and the current portion of long-term debt include:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Note Issuances [Table Text Block] | The following table summarizes the note issuances:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Debt Redemption [Table Text Block] | During the second quarter of 2017, the Company repurchased certain long-term debt obligations with interest rates ranging from 5.875% to 6.875%. The following summarizes the debt repurchase activity:
|
RECEIVABLES (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounts Receivable, Net [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule Of Receivables [Table Text Block] |
|
INVENTORIES (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory, Net [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventories [Table Text Block] |
|
PROPERTY, PLANT AND EQUIPMENT (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property, Plant and Equipment [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property, Plant and Equipment [Table Text Block] |
|
OTHER INTANGIBLE ASSETS (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule Of Intangible Assets By Major Class [Table Text Block] |
|
ACCRUED LIABILITIES (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payables and Accruals [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Accrued Liabilities [Table Text Block] |
|
EQUITY (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Stock by Class [Table Text Block] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Comprehensive Income Loss [Table Text Block] | The components of other comprehensive income/(loss) were as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Accumulated Other Comprehensive Income Loss [Table Text Block] | The accumulated balances related to each component of other comprehensive loss, net of taxes, were as follows:
|
PENSION AND POSTRETIREMENT BENEFIT PLANS (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Compensation and Retirement Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Defined Benefit Plans Disclosures [Table Text Block] | The net periodic benefit cost/(credit) of defined benefit pension plans includes:
|
ACQUISITIONS, DIVESTITURES AND LICENSING ARRANGEMENTS (Acquisitions and Divestitures) (Details) $ in Millions |
9 Months Ended |
---|---|
Sep. 30, 2017
USD ($)
| |
SK Biotek [Member] | |
Divestitures | |
Expected proceeds from divestiture of a business | $ 140 |
Assets held-for-sale | 140 |
Asset impairment charges | 128 |
IFM [Member] | |
Asset Acquisition [Line Items] | |
Asset acquisition payment | 300 |
Contingent development and regulatory milestone payments for first product from the two programs | 1,000 |
Contingent development and regulatory milestone payments for subsequent products | 555 |
Upfront payment for future negotiation rights | 25 |
Upfront payment allocated to research and development expenses | 310 |
Upfront payment allocated to deferred tax asset | 15 |
Flexus [Member] | |
Asset Acquisition [Line Items] | |
Asset acquisition milestone payment | 100 |
Cardioxyl [Member] | |
Asset Acquisition [Line Items] | |
Asset acquisition milestone payment | $ 100 |
ACQUISITIONS, DIVESTITURES AND LICENSING ARRANGEMENTS (Licensing Arrangements) (Details) - Licensing Agreements [Member] $ in Millions |
9 Months Ended |
---|---|
Sep. 30, 2017
USD ($)
| |
Halozyme [Member] | |
Licensing Arrangements [Line Items] | |
Number of original targets | 11 |
License arrangement upfront payment | $ 105 |
Potential contingent milestones | $ 160 |
CytomX [Member] | |
Licensing Arrangements [Line Items] | |
Number of original targets | 4 |
Number of potential additional collaboration targets | 8 |
R&D payments prior to 2017 | $ 75 |
License arrangement upfront payment | 200 |
Potential contingent milestones | 448 |
Biogen [Member] | |
Licensing Arrangements [Line Items] | |
Proceeds from out-licensed arrangements | 300 |
Potential milestone receipts | 410 |
Roche [Member] | |
Licensing Arrangements [Line Items] | |
Proceeds from out-licensed arrangements | 170 |
Potential milestone receipts | $ 205 |
OTHER (INCOME)/EXPENSE (Details) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
Sep. 30, 2017 |
Sep. 30, 2016 |
|
Other Nonoperating Income (Expense) [Abstract] | ||||
Interest expense | $ 48 | $ 42 | $ 145 | $ 127 |
Investment income | (37) | (32) | (104) | (81) |
Provision for restructuring | 28 | 19 | 207 | 41 |
Litigation and other settlements | (1) | (489) | 48 | |
Equity in net income of affiliates | (21) | (19) | (59) | (65) |
Divestiture (gains)/losses | 1 | (21) | (126) | (574) |
Royalties and licensing income | (209) | (158) | (1,093) | (579) |
Transition and other service fees | (12) | (57) | (32) | (184) |
Pension charges | 22 | 19 | 91 | 66 |
Intangible asset impairments | 15 | |||
Equity investment impairment | 45 | |||
Loss on debt redemption | 109 | |||
Other | (11) | (16) | (26) | (57) |
Other (income)/expense | $ (191) | $ (224) | (1,377) | $ (1,198) |
Keytruda patent-infringement litigation settlement amount | 481 | |||
Upfront licensing fees - Biogen and Roche | $ 470 |
INCOME TAXES (Details) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
Sep. 30, 2017 |
Sep. 30, 2016 |
|
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] | ||||
Earnings Before Income Taxes | $ 1,183 | $ 1,559 | $ 4,433 | $ 4,829 |
Provision for Income Taxes | $ 327 | $ 344 | $ 1,129 | $ 1,220 |
Effective tax rate | 27.60% | 22.10% | 25.50% | 25.30% |
Federal statutory tax rate | 35.00% | |||
Increase in Effective Income Tax Rate due to Discrete Items | 3.70% | 3.10% | ||
Reduction of effective tax rate due to adoption of ASU | 2.10% | |||
Minimum [Member] | ||||
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] | ||||
Decrease in Unrecognized Tax Benefits is Reasonably Possible | $ 255 | $ 255 | ||
Maximum [Member] | ||||
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] | ||||
Decrease in Unrecognized Tax Benefits is Reasonably Possible | $ 315 | $ 315 |
EARNINGS PER SHARE (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
Sep. 30, 2017 |
Sep. 30, 2016 |
|
Earnings Per Share [Abstract] | ||||
Net earnings attributable to BMS used for Basic and Diluted EPS Calculation | $ 845 | $ 1,202 | $ 3,335 | $ 3,563 |
Weighted-average common shares outstanding - basic | 1,639 | 1,671 | 1,648 | 1,670 |
Incremental shares attributable to share-based compensation plans | 6 | 8 | 7 | 9 |
Weighted-average common shares outstanding - diluted | 1,645 | 1,679 | 1,655 | 1,679 |
Earnings per share - basic | $ 0.52 | $ 0.72 | $ 2.02 | $ 2.13 |
Earnings per share - diluted | $ 0.51 | $ 0.72 | $ 2.02 | $ 2.12 |
RECEIVABLES (Details) $ in Millions |
9 Months Ended | ||
---|---|---|---|
Sep. 30, 2017
USD ($)
|
Sep. 30, 2016
USD ($)
|
Dec. 31, 2016
USD ($)
|
|
Accounts, Notes, Loans and Financing Receivable [Line Items] | |||
Trade receivables | $ 4,564 | $ 3,948 | |
Charge-Backs and Cash Discounts | (184) | (126) | |
Less allowances | (48) | (48) | |
Net trade receivables | 4,332 | 3,774 | |
Alliance receivables | 878 | 903 | |
Prepaid and refundable income taxes | 334 | 627 | |
Other | 378 | 239 | |
Receivables | 5,922 | $ 5,543 | |
Non-U.S. receivables sold on a nonrecourse basis | $ 460 | $ 470 | |
Percent of aggregate total trade receivables due from three pharmaceutical wholesalers | 64.00% | 66.00% | |
Number Of Largest Pharmaceutical Wholesalers | 3 |
INVENTORIES (Details) - USD ($) $ in Millions |
Sep. 30, 2017 |
Dec. 31, 2016 |
---|---|---|
Inventory, Net [Abstract] | ||
Finished goods | $ 380 | $ 310 |
Work in process | 956 | 988 |
Raw and packaging materials | 224 | 264 |
Total inventories | 1,560 | 1,562 |
Inventories | 1,250 | 1,241 |
Inventories - other assets | 310 | 321 |
Inventory reclassified to assets held-for-sale | $ 120 | |
Inventory pending regulatory approval | $ 54 |
PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($) $ in Millions |
9 Months Ended | ||
---|---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
Dec. 31, 2016 |
|
Property, Plant and Equipment [Line Items] | |||
Gross property, plant and equipment | $ 9,265 | $ 9,173 | |
Less accumulated depreciation | (4,251) | (4,193) | |
Property, plant and equipment | 5,014 | 4,980 | |
Depreciation expense | 509 | $ 319 | |
Land [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Gross property, plant and equipment | 105 | 107 | |
Buildings [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Gross property, plant and equipment | 5,188 | 4,930 | |
Machinery, equipment and fixtures [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Gross property, plant and equipment | 3,034 | 3,287 | |
Construction in Progress [Member] | |||
Property, Plant and Equipment [Line Items] | |||
Gross property, plant and equipment | $ 938 | $ 849 |
OTHER INTANGIBLE ASSETS (Details) - USD ($) $ in Millions |
9 Months Ended | ||
---|---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
Dec. 31, 2016 |
|
Acquired Finite-Lived Intangible Assets [Line Items] | |||
Gross other intangible assets | $ 4,292 | $ 4,469 | |
Less: accumulated amortization | (3,079) | (3,084) | |
Other intangible assets | 1,213 | 1,385 | |
In-process research and development | 32 | 107 | |
Amortization expense | 142 | $ 134 | |
Licensing Agreements [Member] | |||
Acquired Finite-Lived Intangible Assets [Line Items] | |||
Finite-lived intangible assets | 564 | 564 | |
Developed Technology Rights [Member] | |||
Acquired Finite-Lived Intangible Assets [Line Items] | |||
Finite-lived intangible assets | 2,357 | 2,357 | |
Capitalized Software, Intangible Asset [Member] | |||
Acquired Finite-Lived Intangible Assets [Line Items] | |||
Finite-lived intangible assets | $ 1,339 | $ 1,441 |
ACCRUED LIABILITIES (Details) - USD ($) $ in Millions |
Sep. 30, 2017 |
Dec. 31, 2016 |
---|---|---|
Payables and Accruals [Abstract] | ||
Rebates and returns | $ 1,901 | $ 1,680 |
Employee compensation and benefits | 702 | 818 |
Research and development | 689 | 718 |
Dividends | 639 | 660 |
Branded Prescription Drug Fee | 251 | 234 |
Royalties | 249 | 246 |
Restructuring | 121 | 90 |
Pension and postretirement benefits | 41 | 44 |
Litigation and other settlements | 35 | 43 |
Other | 790 | 738 |
Accrued liabilities | $ 5,418 | $ 5,271 |
PENSION AND POSTRETIREMENT BENEFIT PLANS (Details) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | |||
---|---|---|---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
Sep. 30, 2017 |
Sep. 30, 2016 |
Dec. 31, 2016 |
|
Pension, Postretirement And Postemployment Liabilities Statement [Line Items] | |||||
Non-current pension liabilities | $ 477 | $ 477 | $ 600 | ||
Defined contribution plan expense | 46 | $ 49 | 142 | $ 141 | |
Pension Benefits [Member] | |||||
Pension, Postretirement And Postemployment Liabilities Statement [Line Items] | |||||
Service cost - benefits earned during the period | 7 | 6 | 19 | 19 | |
Interest cost on projected benefit obligation | 48 | 45 | 142 | 145 | |
Expected return on plan assets | (104) | (104) | (308) | (314) | |
Amortization of prior service credits | (1) | (1) | (3) | (3) | |
Amortization of net actuarial (gain)/loss | 20 | 22 | 61 | 62 | |
Curtailments and settlements | 22 | 19 | 91 | 66 | |
Special termination benefits | 1 | ||||
Net periodic benefit cost/(credit) | $ (8) | $ (13) | $ 2 | $ (24) |
N CP-H"B 6D%R=C:G^7'3%:M'4EUES?5KG8I@4\$3]8&Z'F^/8C?_U
MV;;]W?>5]8OD?6AGDJRO$KR38/XHV4A)EMXD26_@Y@)5%SC&TWT\Z/&DQM,8
M;^[CD65QE;A1 &ULE5;;CILP$/T5Q'L7;,PE41(I%U6MU$K1
M5FV?G<1)T *FMI-L_[ZV85DPD]WN"V!SSLR9L3V>V8V+)WEF3'G/95')N7]6
MJIX&@=R?64GE Z]9I?\5@'>I9Q9>B
MQ=MTRBZ>XZQ_I6T3^$S@-P0V)8J5/PDGBLS@2,PT^UZ$*TX/W,^F#,$XBOC/
M%V]]]%*D_&/&+D%HQAPG#%]C%@3SZDL*OI7BR/^C\_MM_FZSQ%WD[];I=\FV
MP'Y38!\%]O\(I#<];F'X31*V&JH&T\1ULJ3$H8NKO(HN&_O XZ7\A4_K_E68
M1G:6G-'YJXT74",Z\*4D=WZ'6O_"%D=![8+YP=MFVK/)<=C/3X@M[[CX U!+
M P04 " "86UI+<>KN=[8! #3 P & 'AL+W=O
Z V.V:$ )>X4=:/^G0J.$\Z&IF>T,B#*2E&0\26Z8$JVF>1IS
M)Y.GV#O9:C@98GNEA/E[!(E#1C?T-?'0UHT+"9:GG:CA%[C?W
"[NAKXDFTG0L)5N8];^$;N._]Q?B(+2JU4*"M0$T,
M- 5]V)W.AX"/@!\"1KO:D]#)%?$Y!)_K@B;!$$BH7%#@?KG!(T@9A+R-7[,F
M74H&XGK_JOXQ]NY[N7(+CRA_BMIU!
.>3M]Y[*6ERG9-+$)HQQPE#5YC=@B!>?0E!MT(#M]T"L4(13+UF.@=-E[,KNU M3%SRL=E/+:^F$Y\TXS\9GZ
M6_\7/@S4KTQ=FE8')VGL[/ WO)+2@,TE>K+?86UG^&1PJ(S;KNU>#8-L,(SL
MQB%-IC]%\0=02P,$% @ F%M:2SY>=<&W 0 TP, !D !X;"]W;W)K
M
MS"'-X48:M#56";.$Z.E&;0<917V65B
M[WF\E#_P:=R_"MMTVI&K\7BU\0)J8SR@E=T=SE"++VP))-0^;-_CWDYS-@7>
M]/,38LL[+GX#4$L#!!0 ( )A;6DMC7(VQU0$ )T$ 9 >&PO=V]R
M:W-H965TF@Q9O*F.U\&C:FKG.
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M'W8INP6A"7,>,7R!VUB]S;PFMU*I59\/*L)2?Z@ZJ?[4[HF3>@'*J:-K+BC2/H<>UNT/,6
M8^-@+7Y5]"I'8\>DLN?\S4R^'M:N;R*BC!;*0!#]NM 7RIA!TG'\Z4'=@=,X
MCL26,^D**V!+E#4>8%7H7/CVEH%UN
M(\9;H/-)RO:S.=_$!;I[T$7C@,K8$1BBYZ(PL7"GSH$BP4-IC=PN(7&Y&Z[)
M[1&
MJV<%!T!-+=XD=G@&."F^3.(8$/"(V!*W%G,(E6F,I1"IG##!B+2*4;Q\2H"I
MH!8OMX'>GIE#8-0AN2-C4X7L/OH29V(Y*9](9O@0@,18AT'MAT,!.(+$L$'P
M1TMS=KMMO"08(DQFSS$,*I97DMX!<^+-$E"YT3Y5Z"39QHN]' \OU2C>GFKX
MQ6?DJ__]_P[\=O\'$H=(&R6VYCJ%&L&I,89$%FBL%.(Z9A$\U#E%*I7,$/$K
MG]&VAYIY"*J-[JESN!J*+\\1&5Q(:JI^'6D+NG@S1-X
!AZ
MG- C&'+!\;F+90AR.Q$6:XRF(#NM]^(2TR2PJ"EW6H;+,* L
M@79+_9RDG]@^065EU;#;4T-@%W?ABQ2=G'T*G]P0(4RK[5!G+&91;KTX8E>]
MEOSTU:3PG<^V),_OM/.V55Q*X+=S+W")-@<7"_9.>?7(@G?SG6F);,-VG2**
M7U^GL3I([*LSOP['AN6@IA/9;*B<&Y',-204Y>BMT1>]1^Z,90;0FHO[XBY4
MW)Z.A7XSD [%KRIOCP?3[;A:887MMXB^MW
+F^EB&I1ZI R1&L, QB)F4O$Q,69:$.H@M1]/PF= 0
M^:+6\HU>EQK,6WPMM)YLFY>HR6>CVZ?VK3GK@;U9&A"/V#60._VAC(0_@+0'
M/ !^3/[RN+11]E&0!4+H9]<%Z#H0"3BNA49F>.- G2@)UK7
MPLX>J=6